MIME-Version: 1.0 X-Document-Type: Workbook Content-Type: multipart/related; boundary="----=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Workbook.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

This page should be opened with Microsoft Excel XP or newer.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet01.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Document and Entity Information (USD  $) In Billions, except Share data	3 Months Ended
Apr. 03, 2011	May 09, 2011	Jul. 04, 2010
Document Information [Line Items]
Document type	10-Q
Amendment flag	false
Document period end date	Apr 3, 2011
Document fiscal year focus	2011
Document fiscal period focus	Q1
Entity Information [Line Items]
Entity registrant name	PFIZER INC
Entity central index key	0000078003
Current fiscal year end date	--12-31
Entity well known seasoned issuer	Yes
Entity voluntary filers	No
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity public float			$ 114
Entity common stock shares outstanding		7,901,130,426

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet02.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD  $) In Millions, except Per Share data	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Revenues	$ 16,502		$ 16,576
Costs and expenses:
Cost of sales	3,693	[1]	4,202	[1]
Selling, informational and administrative expenses	4,503	[1]	4,403	[1]
Research and development expenses	2,091	[1]	2,221	[1]
Amortization of intangible assets	1,376		1,409
Acquisition-related in-process research and development charges			74
Restructuring charges and certain acquisition-related costs	894		706
Other deductions - net	827		412
Income from continuing operations before provision for taxes on income	3,118		3,149
Provision for taxes on income	894		1,135
Income from continuing operations	2,224		2,014
Discontinued operations:
Income from operations - net of tax	10		19
Gain on sale of discontinued operations - net of tax			2
Discontinued operations--net of tax	10		21
Net income before allocation to noncontrolling interests	2,234		2,035
Less: Net income attributable to noncontrolling interests	12		9
Net income attributable to Pfizer Inc.	$ 2,222		$ 2,026
Earnings per common share - basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.28		$ 0.25
Discontinued operations - net of tax (in dollars per share)	$ 0		$ 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.28		$ 0.25
Earnings per common share - diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.28		$ 0.25
Discontinued operations - net of tax (in dollars per share)	$ 0		$ 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.28		$ 0.25
Weighted-average shares used to calculate earnings per common share:
Basic (in shares)	7,982		8,061
Diluted (in shares)	8,035		8,101
Cash dividends paid per common share (in dollars per share)	$ 0.2		$ 0.18
[1]	Exclusive of amortization of intangible assets, except as disclosed in Note 11.B Goodwill and Other Intangible Assets: Other Intangible Assets.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet03.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD  $) In Millions	Apr. 03, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 730	[1]	$ 1,735
Short-term investments	23,279	[1]	26,277
Accounts receivable, less allowance for doubtful accounts	15,182	[1]	14,426
Short-term loans	406	[1]	467
Inventories	8,467	[1]	8,275
Taxes and other current assets	8,755	[1]	8,394
Assets of discontinued operations and other assets held for sale	1,425	[1]	1,439
Total current assets	58,244	[1]	61,013
Long-term investments and loans	9,811	[1]	9,747
Property, plant and equipment, less accumulated depreciation	18,833	[1]	18,645
Goodwill	44,853	[1]	43,928
Identifiable intangible assets, less accumulated amortization	58,497	[1]	57,555
Taxes and other noncurrent assets	4,718	[1]	4,126
Total assets	194,956	[1]	195,014
Liabilities and Shareholders' Equity
Short-term borrowings, including current portion of long-term debt	6,093	[1]	5,603
Accounts payable	3,750	[1]	3,994
Dividends payable	1	[1]	1,601
Income taxes payable	1,958	[1]	951
Accrued compensation and related items	1,849	[1]	2,080
Other current liabilities	15,338	[1]	14,256
Liabilities of discontinued operations	182	[1]	151
Total current liabilities	29,171	[1]	28,636
Long-term debt	35,308	[1]	38,410
Pension benefit obligations	5,929	[1]	6,194
Postretirement benefit obligations	3,041	[1]	3,035
Noncurrent deferred tax liabilities	19,414	[1]	18,628
Other taxes payable	6,590	[1]	6,245
Other noncurrent liabilities	4,970	[1]	5,601
Total liabilities	104,423	[1]	106,749
Preferred stock	49	[1]	52
Common stock	444	[1]	444
Additional paid-in capital	70,925	[1]	70,760
Employee benefit trusts	(6)	[1]	(7)
Treasury stock	(24,215)	[1]	(22,712)
Retained earnings	44,926	[1]	42,716
Accumulated other comprehensive loss	(2,056)	[1]	(3,440)
Total Pfizer Inc. shareholders' equity	90,067	[1]	87,813
Equity attributable to noncontrolling interests	466	[1]	452
Total shareholders' equity	90,533	[1]	88,265
Total liabilities and shareholders' equity	$ 194,956	[1]	$ 195,014
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet04.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Operating Activities:
Net income before allocation to noncontrolling interests	$ 2,234		$ 2,035
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization	2,104		2,051
Share-based compensation expense	122		138
Asset write-offs and impairment charges	165		59
Acquisition-related in-process research and development charges			74
Deferred taxes from continuing operations	(120)		840
Other non-cash adjustments	(2)		260
Benefit plan contributions (in excess of)/less than expense	(383)		163
Other changes in assets and liabilities, net of acquisitions and divestitures	522		(11,980)
Net cash provided by/(used in) operating activities	4,642		(6,360)
Investing Activities:
Purchases of property, plant and equipment	(250)		(305)
Purchases of short-term investments	(3,352)		(2,178)
Proceeds from redemptions and sales of short-term investments, net	8,406		11,388
Purchases of long-term investments	(1,932)		(858)
Proceeds from redemptions and sales of long-term investments	888		1,127
Acquisitions, net of cash acquired	(3,169)
Other investing activities	134		220
Net cash provided by investing activities	725		9,394
Financing Activities:
Increase in short-term borrowings	2,682		1,892
Principal payments on short-term borrowings, net	(2,220)		(3,663)
Principal payments on long-term debt	(3,878)		(9)
Purchases of common stock	(1,430)
Cash dividends paid	(1,591)		(1,441)
Other financing activities	33		10
Net cash used in financing activities	(6,404)		(3,211)
Effect of exchange-rate changes on cash and cash equivalents	32		(42)
Net decrease in cash and cash equivalents	(1,005)		(219)
Cash and cash equivalents at beginning of period	1,735		1,978
Cash and cash equivalents at end of period	730	[1]	1,759
Supplemental Cash Flow Information:
Cash (refunded)/paid for income taxes	(134)		10,547
Cash paid for interest	$ 687		$ 792
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet05.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Basis of Presentation	3 Months Ended
Apr. 03, 2011
Basis of Presentation [Abstract]
Basis of Presentation [Text Block]	Note 1. Basis of Presentation We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 27, 2011, and February 28, 2010. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to discontinued operations (see Note 4. Discontinued Operations) and segment reporting (see Note 15. Segment, Product and Geographic Area Information). On January 31, 2011, we completed the tender offer for all of the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and acquired approximately 92.5% of the outstanding shares for approximately  $3.3 billion in cash. On February 28, 2011, we acquired the remaining outstanding shares of King for approximately  $300 million in cash (for additional information, see Note 3. Acquisition of King Pharmaceuticals, Inc.). Commencing from January 31, 2011, our financial statements include the assets, liabilities, operating results and cash flows of King. As a result, and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the quarter ended April 3, 2011 reflect approximately two months of King’s U.S. operations and approximately one month of King’s international operations. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this document.  The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2010.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet06.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Adoption of New Accounting Policies	3 Months Ended
Apr. 03, 2011
Adoption of New Accounting Policies [Abstract]
Adoption of New Accounting Policies [Text Block]	Note 2. Adoption of New Accounting Policies   The provisions of the following new accounting standards were adopted as of January 1, 2011 and did not have a significant impact on our condensed consolidated financial statements: ● New guidelines that address the recognition and presentation of the annual fee paid by pharmaceutical companies beginning on January 1, 2011 to the U.S. Treasury as a result of U.S. Healthcare Legislation. As a result of adopting this new standard, we are recording the annual fee ratably throughout the year in the Selling, informational and administrative expenses line item in our condensed consolidated statement of income. ● An amendment to the guidelines that address the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet07.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of King Pharmaceuticals Inc	3 Months Ended
Apr. 03, 2011
Acquisition of King Pharmaceuticals Inc [Abstract]
Acquisition of King Pharmaceuticals Inc [Text Block]	Note 3. Acquisition of King Pharmaceuticals, Inc. On January 31, 2011 (the acquisition date), we completed our tender offer for all of the outstanding shares of common stock of King at a purchase price of  $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for  $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately  $3.6 billion in cash ( $3.2 billion, net of cash acquired). King’s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.   The following table summarizes the provisional recording, primarily at fair value, of the assets acquired and liabilities assumed as of the acquisition date:  (millions of dollars)   Amounts Recognized as of Acquisition Date (Provisional)           Working capital, excluding inventories    $ 210   Inventories     340   Property, plant and equipment     413   Identifiable intangible assets, excluding in-process research and development     1,781   In-process research and development     301   Net tax accounts     (384 ) All other long-term assets and liabilities, net     114   Total identifiable net assets     2,775   Goodwill     780   Net assets acquired/total consideration transferred    $ 3,555   As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was  $200 million, virtually all of which is expected to be collected. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following: ● the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer; ● any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and ● the value of the going-concern element of King’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately). Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see Note 11. Goodwill and Other Intangible Assets for additional information). The assets and liabilities arising from contingencies recognized at acquisition date, which are subject to change, are not significant to Pfizer’s financial statements. The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change: ● Amounts for intangibles, inventory and property, plant and equipment (PP&E), pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets. ● Amounts for environmental contingencies, pending the finalization of our assessment and valuation of environmental matters. ● Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases. ● Amounts for income tax assets, receivables and liabilities pending the filing of King’s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used. ● The allocation of goodwill among reporting units.   The following table presents information for King that is included in Pfizer’s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer’s first-quarter 2011 domestic and international quarter-ends:  (millions of dollars)   King’s Operations Included in Pfizer’s First Quarter 2011 Results           Revenues    $ 224   Loss from continuing operations attributable to Pfizer Inc. common shareholders(a)     (69 ) (a) Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ( $57 million pre-tax), amortization of identifiable intangible assets acquired from King ( $29 million pre-tax) and restructuring and integration costs ( $95 million pre-tax).   The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:     Pro Forma Consolidated Results       Three Months Ended   (millions of dollars, except per share  data)   April 3, 2011     April 4, 2010                 Revenues    $ 16,611      $ 16,949   Income from continuing operations attributable to Pfizer Inc. common shareholders     2,313       1,910   Diluted earnings per share attributable to Pfizer Inc. common shareholders     0.29       0.24     The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pro forma pre-tax amounts: ● Elimination of King’s historical intangible asset amortization expense ( $6 million in 2011 and  $41 million in 2010). ● Additional amortization expense (approximately  $14 million in 2011 and  $43 million in 2010) related to the fair value of identifiable intangible assets acquired. ● Additional depreciation expense (approximately  $1 million in 2011 and  $3 million in 2010) related to the fair value adjustment to property, plant and equipment acquired. ● Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (elimination of  $57 million charge in 2011 and addition of  $57 million charge in 2010). ● Adjustment for acquisition-related costs directly attributable to the acquisition (elimination of  $117 million of charges in 2011 and addition of  $117 million of charges in 2010, reflecting charges incurred by both King and Pfizer).

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet08.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Discontinued Operations	3 Months Ended
Apr. 03, 2011
Discontinued Operations [Abstract]
Discontinued Operations [Text Block]	Note 4. Discontinued Operations   We evaluate our businesses and product lines periodically for their strategic fit within our operations. In the first quarter of 2011, we decided to sell our Capsugel business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business have been reclassified into Discontinued operations–– net of tax in the Condensed Consolidated Statements of Income, and the assets and liabilities associated with this business have been adjusted to fair value, less costs to sell, and reclassified into Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the Condensed Consolidated Balance Sheets.   On April 4, 2011, we announced that we had entered into an agreement to sell Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. for  $2.375 billion in cash. The sale is subject to customary closing conditions, including regulatory approval in certain jurisdictions, such as the U.S. and the European Union, among others. We expect the transaction to be completed in the third quarter of 2011, assuming receipt of the required regulatory clearances and the satisfaction of other closing conditions.   The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations—net of tax in our Condensed Consolidated Statements of Income:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Revenues    $ 177      $ 174   Pre-tax income from discontinued operations    $ 28      $ 30   Provision for taxes     (18 )     (11 ) Income from discontinued operations––net of tax     10       19   Pre-tax gain on sale of discontinued operations     ––       3   Provision for income taxes     ––       (1 ) Discontinued operations––net of tax    $ 10      $ 21   The following assets and liabilities, which include assets and liabilities held for sale related to our Capsugel business, and other assets held for sale, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets: (millions of dollars)   April 3, 2011     Dec. 31, 2010                 Accounts receivable    $ 179      $ 186   Inventories     144       130   Taxes and other current assets     39       47   Property, plant and equipment     993       1,009   Goodwill     19       19   Identifiable intangible assets     6       3   Taxes and other noncurrent assets     45       45   Assets of discontinued operations and other assets held for sale    $ 1,425      $ 1,439                     Current liabilities    $ 133      $ 124   Other liabilities     49       27   Liabilities of discontinued operations    $ 182      $ 151   Net cash flows of our discontinued operations from each of the categories of operating, investing and financing activities were not significant.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet09.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Costs Associated with Cost-Reduction Initiatives and Acquisition Activity	3 Months Ended
Apr. 03, 2011
Costs Associated With Cost - Reduction Initiatives And Acquisition Activity [Abstract]
Costs Associated with Cost-Reduction Initiatives and Acquisition Activity [Text Block]	Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity We often incur significant costs in connection with acquiring, restructuring and integrating acquired businesses and in connection with our global cost-reduction initiatives. For example:   ● for our cost-reduction initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and   ● for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and systems integration) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.   On February 1, 2011, we announced a new research and productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.   We incurred the following costs in connection with our cost-reduction initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Transaction costs(a)    $ 10      $ 9   Integration costs(b)     179       208   Restructuring charges(c):                 Employee termination costs     667       458   Asset impairments     25       6   Other     13       25   Restructuring charges and certain acquisition-related costs     894       706     Additional depreciation––asset restructuring (d)                 Cost of sales     172       13   Selling, informational and administrative expenses     7       60   Research and development expenses     64       20   Total additional depreciation––asset restructuring     243       93     Implementation costs(e)                 Research and development expenses     10       ––   Total implementation costs     10       ––   Total costs associated with cost-reduction initiatives and acquisition activity    $ 1,147      $ 799   (a) Transaction costs represent external costs directly related to business combinations and primarily include expenditures for banking, legal, accounting and other similar services. (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and systems integration. (c) From the beginning of our cost-reduction and transformation initiatives in 2005 through April 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 53,500 employees, mainly in manufacturing and sales and research of which approximately 37,900 employees have been terminated as of April 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities. These restructuring charges in 2011 are associated with the following: Primary Care operating segment ( $46 million), Specialty Care and Oncology operating segment ( $35 million), Established Products and Emerging Markets operating segment ( $3 million), Animal Health and Consumer Healthcare operating segment ( $10 million), Nutrition operating segment ( $2 million), Worldwide Research and Development ( $422 million) and Corporate ( $187 million). (d) Additional depreciation – asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction initiatives. The components of restructuring charges associated with all of our cost-reduction initiatives and acquisition activity follow:     Costs Incurred     Activity     Accrual   (millions of dollars)     2005-2011     Through April 3, 2011(a)     As of April 3, 2011(b)                         Employee termination costs    $ 9,478      $ 7,160      $ 2,318   Asset impairments     2,333       2,333       ––   Other     914       822       92   Total restructuring charges    $ 12,725      $ 10,315      $ 2,410   (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $1.7 billion) and Other noncurrent liabilities ( $700 million).

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet10.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Other (Income)/Deductions - Net	3 Months Ended
Apr. 03, 2011
Other (Income)/Deductions-Net [Abstract]
Other (Income)/Deductions-Net [Text Block]	Note 6. Other (Income)/Deductions—Net The following table sets forth details related to amounts recorded in Other deductions––net:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Interest income(a)    $ (105 )    $ (112 ) Interest expense(a)     458       522   Net interest expense     353       410   Royalty-related income     (171 )     (142 ) Net gain on asset disposals     (12 )     (45 ) Certain legal matters, net(b)     501       137   Certain asset impairment charges(c)     157       ––   Other, net     (1 )     52   Other deductions––net    $ 827      $ 412   (a) Interest income decreased in 2011 due to lower interest rates. Interest expense decreased in 2011 due to lower long- and short-term debt balances and the conversion of some fixed-rate liabilities to floating-rate liabilities. (b) In 2011, primarily relates to a charge for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies). (c) In 2011, relates to an IPR&D compound acquired as part of our acquisition of Wyeth.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet11.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Taxes on Income	3 Months Ended
Apr. 03, 2011
Taxes on Income [Abstract]
Taxes on Income [Text Block]	Note 7. Taxes on Income Our effective tax rate for continuing operations was 28.7% for the first quarter of 2011, compared to 36.0% for the first quarter of 2010. The lower tax rate for the first quarter of 2011 is primarily the result of: ● the extension of the U.S. research and development credit, which was signed into law on December 17, 2010; ● the change in the jurisdictional mix of earnings; and ● the tax impact of the charges incurred for certain legal matters (see Note 14. Legal Proceedings and Contingencies).

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet12.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income/(Loss)	3 Months Ended
Apr. 03, 2011
Comprehensive Income/(Loss) [Abstract]
Comprehensive Income/(Loss) [Text Block]	Note 8. Comprehensive Income/(Loss) The components of comprehensive income/(loss) follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Net income before allocation to noncontrolling interests    $ 2,234      $ 2,035   Other comprehensive income/(loss):                 Currency translation adjustment and other     1,541       (2,749 ) Net unrealized (losses)gains on derivative financial instruments     (135 )     134   Net unrealized losses on available-for-sale securities     (24 )     (15 ) Benefit plan adjustments     2       117   Total other comprehensive income(loss)     1,384       (2,513 ) Total comprehensive income/(loss) before allocation to noncontrolling interests     3,618       (478 ) Less: Comprehensive income(loss) attributable to noncontrolling interests     16       (10 ) Comprehensive income/(loss) attributable to Pfizer Inc.    $ 3,602      $ (468 )

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet13.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments	3 Months Ended
Apr. 03, 2011
Financial Instruments [Abstract]
Financial Instruments Disclosure [Text Block]	Note 9. Financial Instruments A. Selected Financial Assets and Liabilities Information about certain of our financial assets and liabilities follows: (millions of dollars)   April 3, 2011     Dec. 31, 2010   Selected financial assets measured at fair value on a recurring basis (a) :             Trading securities    $ 155      $ 173   Available-for-sale debt securities(b)     29,482       32,699   Available-for-sale money market funds     1,396       1,217   Available-for-sale equity securities, excluding money market funds(b)     343       230   Derivative financial instruments in receivable positions(c):                 Interest rate swaps     339       603   Foreign currency swaps     268       128   Foreign currency forward-exchange contracts     134       494   Total     32,117       35,544   Other selected financial assets(d):                 Held-to-maturity debt securities, carried at amortized cost(b)     848       1,178   Private equity securities, carried at cost or equity method     1,156       1,134   Short-term loans, carried at cost     406       467   Long-term loans, carried at cost     237       299   Total     2,647       3,078   Total selected financial assets (e)    $ 34,764      $ 38,622   Financial liabilities measured at fair value on a recurring basis(a):                 Derivative financial instruments in a liability position(f):                 Foreign currency swaps    $ 572      $ 623   Foreign currency forward-exchange contracts     304       257   Interest rate swaps     7       4   Total     883       884   Other financial liabilities:                 Short-term borrowings, carried at historical proceeds, as adjusted(d), (g)     6,093       5,603   Long-term debt, carried at historical proceeds, as adjusted(h), (i)     35,308       38,410   Total     41,401       44,013   Total selected financial liabilities    $ 42,284      $ 44,897   (a) Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are  $109 million as of April 3, 2011 and  $105 million as of December 31, 2010 of investments that use Level 1 inputs in the calculation of fair value, and  $125 million that use Level 3 inputs as of April 3, 2011. (b) Gross unrealized gains and losses are not significant. (c) Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency swaps with fair values of  $70 million and foreign currency forward-exchange contracts with fair values of  $69 million at April 3, 2011; and foreign currency forward-exchange contracts with fair values of  $326 million and foreign currency swaps with fair values of  $17 million at December 31, 2010. (d) The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant at April 3, 2011 or December 31, 2010. (e) The decrease in selected financial assets is primarily due to sales of investments, the proceeds from which were used to fund our acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). (f) Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of  $107 million and foreign currency swaps with fair values of  $37 million at April 3, 2011; and foreign currency forward-exchange contracts with fair values of  $186 million and foreign currency swaps with fair values of  $93 million at December 31, 2010. (g) Includes foreign currency borrowings with fair values of  $920 million at April 3, 2011 and  $2.0 billion at December 31, 2010, which are used to hedge the exposure of certain foreign currency denominated net investments. (h) Includes foreign currency debt with fair values of  $838 million at April 3, 2011 and  $880 million at December 31, 2010, which are used to hedge the exposure of certain foreign currency denominated net investments. (i) The fair value of our long-term debt is  $38.7 billion at April 3, 2011 and  $42.3 billion at December 31, 2010.   These selected financial assets and liabilities are presented in the Condensed Consolidated Balance Sheets as follows: (millions of dollars)   April 3, 2011     Dec. 31, 2010   Assets             Cash and cash equivalents    $ 527      $ 906   Short-term investments     23,279       26,277   Short-term loans     406       467   Long-term investments and loans     9,811       9,747   Taxes and other current assets(a)     324       515   Taxes and other noncurrent assets(b)     417       710   Total selected financial assets    $ 34,764      $ 38,622   Liabilities                 Short-term borrowings, including current portion of long-term debt    $ 6,093      $ 5,603   Other current liabilities(c)     435       339   Long-term debt     35,308       38,410   Other noncurrent liabilities(d)     448       545   Total selected financial liabilities    $ 42,284      $ 44,897   (a) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $153 million), foreign currency forward-exchange contracts ( $134 million) and interest rate swaps ( $37 million) and at December 31, 2010, include foreign currency forward-exchange contracts ( $494 million) and foreign currency swaps ( $21 million). (b) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $115 million) and interest rate swaps ( $302 million) and at December 31, 2010, include interest rate swaps ( $603 million) and foreign currency swaps ( $107 million). (c) At April 3, 2011, derivative instruments at fair value include foreign currency forward-exchange contracts ( $304 million), foreign currency swaps ( $129 million) and interest rate swaps ( $2 million) and at December 31, 2010, include foreign currency forward-exchange contracts ( $257 million), foreign currency swaps ( $79 million) and interest rate swaps ( $3 million). (d) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $443 million) and interest rate swaps ( $5 million) and at December 31, 2010, include foreign currency swaps ( $544 million) and interest rate swaps ( $1 million). There were no significant impairments of financial assets recognized in the first quarter of 2011 or 2010. B. Investments in Debt and Equity Securities The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 3, 2011, follow:     Years         (millions of dollars)   Within 1     Over 1 to 5     Over 10     Total at April 3, 2011   Available-for-sale debt securities:                         Western European and other government debt    $ 17,725      $ 969      $ ––      $ 18,694   Corporate debt     1,372       2,447       ––       3,819   Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities     ––       2,627       ––       2,627   Western European and other government agency debt     1,487       168       62       1,717   Supranational debt     937       647       ––       1,584   Reverse repurchase agreements     759       ––       ––       759   U.S. government Federal Deposit Insurance Corporation guaranteed debt     ––       155       ––       155   Other asset-backed securities     16       25       48       89   Certificates of deposit     38       ––       ––       38   Held-to-maturity debt securities:                                 Certificates of deposit and other     712       136       —       848   Total debt securities    $ 23,046      $ 7,174      $ 110      $ 30,330   Trading securities                             155   Available-for-sale money market funds                             1,396   Available-for-sale equity securities, excluding money market funds                             343   Total                            $ 32,224   C. Short-Term Borrowings Short-term borrowings include amounts for commercial paper of  $900 million as of April 3, 2011 and  $1.2 billion as of December 31, 2010. D. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk—As of April 3, 2011, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures is  $44.5 billion. The derivative financial instruments primarily hedge or offset exposures in euro, Japanese yen and U.K. pound.   Interest Rate Risk—As of April 3, 2011, the aggregate notional amount of interest rate derivative financial instruments is  $13 billion. The derivative financial instruments hedge U.S. dollar and euro fixed-rate debt. Information about gains/(losses) incurred to hedge or offset foreign exchange or interest rate risk is as follows:     Amount of Gains/(Losses) Recognized in OID(a) (b) (c)     Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a) (d)     Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a) (d)   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010   Three Months Ended                                     Derivative Financial Instruments in Fair Value   Hedge Relationships(b)                                      Interest rate swaps    $ ––      $ ––      $ ––      $ ––      $ ––      $ ––    Foreign currency swaps     (1 )     ––       ––       ––       ––       ––                                                     Derivative Financial Instruments in Cash Flow   Hedge Relationships                                                  Foreign currency swaps    $ ––      $ ––      $ 305      $ (438 )    $ 506      $ (628 )  Foreign currency forward-exchange contracts     ––       ––       2       ––       4       1                                                     Derivative Financial Instruments in Net   Investment Hedge Relationships                                                  Foreign currency swaps    $ 2      $ 1      $ 33      $ 11      $ ––      $ ––                                                     Derivative Financial Instruments Not   Designated as Hedges                                                  Foreign currency swaps    $ 30      $ 4      $ ––      $ ––      $ ––      $ ––    Foreign currency forward-exchange contracts     (197 )     (890 )     ––       ––       ––       ––                                                     Non-Derivative Financial Instruments in Net   Investment Hedge Relationships                                                  Foreign currency short-term borrowings    $ ––      $ ––      $ 43      $ 31      $ ––      $ ––    Foreign currency long-term debt     ––       ––       28       16       ––       ––                                                      Total    $ (166 )    $ (885 )    $ 411      $ (380 )    $ 510      $ (627 ) (a) OID = Other (income)/deductions—net, included in the income statement account, Other deductions—net. OCI = Other comprehensive income/(loss), included in the balance sheet account Accumulated other comprehensive loss. (b) Also includes gains and losses attributable to the hedged risk in fair value hedge relationships. (c) There was no significant ineffectiveness in the first quarters of 2011 or 2010. (d) Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Net unrealized (losses)/gains on derivative financial instruments. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Currency translation adjustment and other. For information about the fair value of our derivative financial instruments, and the impact on our Condensed Consolidated Balance Sheets, see Note 9A. Financial Instruments: Selected Financial Assets and Liabilities. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. The aggregate fair value of these derivative instruments that are in a liability position is  $297 million, for which we have posted collateral of  $203.6 million in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s Investors Service, on April 3, 2011, we would have been required to post an additional  $93.9 million of collateral to our counterparties. The collateral advanced receivables are reported in Cash and cash equivalents. E. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of April 3, 2011, we had  $3.1 billion due from a well-diversified, highly rated group (S&P ratings of primarily A+ or better) of bank counterparties around the world. See Note 9B. Financial Instruments: Investments in Debt and Equity Securities for a distribution of our investments. In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under master netting agreements with financial institutions. These agreements contain provisions that provide for the ability for collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of April 3, 2011, we received cash collateral of  $529.7 million against various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. The collateral received obligations are reported in Short-term borrowings, including current portion of long-term debt.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet14.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories	3 Months Ended
Apr. 03, 2011
Inventories [Abstract]
Inventories [Text Block]	Note 10. Inventories The components of inventories follow: (millions of dollars)   April 3, 2011     Dec. 31, 2010                 Finished goods    $ 3,739      $ 3,665   Work-in-process     3,909       3,727   Raw materials and supplies     819       883   Total inventories(a)    $ 8,467      $ 8,275   (a) Certain amounts of inventories are in excess of one year’s supply. There are no recoverability issues associated with these quantities.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet15.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Goodwill and Other Intangible Assets	3 Months Ended
Apr. 03, 2011
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets [Text Block]	Note 11. Goodwill and Other Intangible Assets A. Goodwill The changes in the carrying amount of goodwill for the three months ended April 3, 2011, follow: (millions of dollars)   Primary Care     Specialty Care and Oncology     Established Products and Emerging Markets     Animal Health and Consumer Healthcare     Nutrition     To be Allocated(a)     Total                                               Balance, December 31, 2010    $        $        $        $ 2,449      $ 496      $ 40,983      $ 43,928   Additions(b)                             ––       ––       780       780   Other(c)                             12       5       128       145   Balance, April 3, 2011    $        $        $        $ 2,461      $ 501      $ 41,891      $ 44,853   (a) The amount to be allocated includes the former Biopharmaceutical goodwill (see below), as well as newly acquired goodwill from our acquisition of King, for which the allocation to reporting units is pending (see Note 3. Acquisition of King Pharmaceuticals, Inc. for additional information). (b) Relates to our acquisition of King and is subject to change until we complete the recording of the assets acquired and liabilities assumed from King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). The allocation of King goodwill among our reporting units has not yet been completed, but will be completed within one year of the acquisition date. (c) Primarily reflects the impact of foreign exchange. Our company was previously managed through two operating segments (Biopharmaceutical and Diversified), and is now managed through five operating segments (see Note 15. Segment, Product and Geographic Area Information for further information). As a result of this change, the goodwill previously associated with our Biopharmaceutical operating segment is required to be allocated among the Primary Care, Specialty Care and Oncology, and Established Products and Emerging Markets operating segments. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit. Therefore, we have not yet completed the allocation, but we expect that it will be completed in the current year. B. Other Intangible Assets The components of identifiable intangible assets follow:     April 3, 2011     December 31, 2010   (millions of dollars)   Gross Carrying Amount     Accumulated Amortization     Identifiable Intangible Assets, less Accumulated Amortization     Gross Carrying Amount     Accumulated Amortization     Identifiable Intangible Assets, less Accumulated Amortization                                         Finite-lived intangible assets:                                     Developed technology rights    $ 71,003      $ (28,029 )    $ 42,974      $ 68,432      $ (26,223 )    $ 42,209   Brands     1,635       (628 )     1,007       1,626       (607 )     1,019   License agreements     637       (277 )     360       637       (248 )     389   Trademarks and other     541       (337 )     204       533       (324 )     209   Total amortized finite-lived intangible assets     73,816       (29,271 )     44,545       71,228       (27,402 )     43,826   Indefinite-lived intangible assets:                                                 Brands     10,287       ––       10,287       10,219       —       10,219   In-process research and development     3,593       ––       3,593       3,438       —       3,438   Trademarks     72       ––       72       72       —       72   Total indefinite-lived intangible assets     13,952       ––       13,952       13,729       —       13,729   Total identifiable intangible assets(a)    $ 87,768      $ (29,271 )    $ 58,497      $ 84,957      $ (27,402 )    $ 57,555   (a) The increase is primarily related to the assets acquired as part of the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.) and the impact of foreign exchange, partially offset by amortization of intangible assets. At April 3, 2011, our identifiable intangible assets are associated with the following, as a percentage of net book value:   ● Developed Technology Rights: Specialty Care (62%); Primary Care (17%); Established Products (17%); Animal Health (2%); Oncology (1%) and Nutrition (1%) ● Finite-Lived Brands: Consumer Healthcare (56%); Established Products (30%); and Animal Health (14%) ● Indefinite-Lived Brands: Consumer Healthcare (51%); Established Products (27%); and Nutrition (22%) ● IPR&D: Specialty Care (70%); Worldwide Research and Development (18%); Primary Care (6%); Oncology (3%); Established Products (2%); and Consumer Healthcare (1%) For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield a successful product. The nature of the biopharmaceutical business is high-risk and requires that we invest in a large number of projects as a mechanism for achieving a successful portfolio of approved products. As such, it is likely that many of these IPR&D assets will become impaired and be written-off at some time in the future. Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was  $1.4 billion for both the first quarter of 2011 and 2010.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet16.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Pension and Postretirement Benefit Plans	3 Months Ended
Apr. 03, 2011
Pension and Postretirement Benefit Plans [Abstract]
Pension and Postretirement Benefit Plans [Text Block]	Note 12. Pension and Postretirement Benefit Plans The components of net periodic benefit costs of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, follow:     Pension Plans             U.S. Qualified     U.S. Supplemental (Non-Qualified)     International     Postretirement Plans   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010                                                     For the Three Months Ended:                                                 Service cost    $ 90      $ 94      $ 9      $ 8      $ 62      $ 60      $ 17      $ 22   Interest cost     185       191       19       19       111       111       49       54   Expected return on plan assets     (221 )     (202 )     ––       ––       (109 )     (112 )     (9 )     (8 ) Amortization of:                                                                    Actuarial losses     35       38       9       7       21       17       4       ––      Prior service credits     (2 )     ––       (1 )     (1 )     (1 )     (1 )     (14 )     (4 ) Curtailments and settlements––net     17       (33 )     12       (1 )     (2 )     1       (6 )     ––   Special termination benefits     5       14       7       90       3       1       ––       6   Net periodic benefit costs    $ 109      $ 102      $ 55      $ 122      $ 85      $ 77      $ 41      $ 70   The increase in net periodic benefit costs in the first three months of 2011, compared to the first three months of 2010, for our U.S. qualified plans was primarily driven by curtailment gains recognized in the prior year associated with Wyeth-related restructuring initiatives partially offset by higher expected return on plan assets. The decrease in net periodic benefit costs in the first three months of 2011, compared to the first three months of 2010, for our U.S. supplemental (non-qualified) pension plans was primarily driven by special termination benefits recognized in the prior-year period for certain executives as part of Wyeth-related restructuring initiatives. The decrease in net periodic benefit costs in the first three months of 2011, compared to the first three months of 2010, for our postretirement plans was primarily driven by the harmonization of the legacy Wyeth postretirement plans during 2010. For the first quarter of 2011, we contributed from our general assets:  $400 million to our U.S. qualified pension plans,  $121 million to our international pension plans,  $92 million to our U.S. supplemental (non-qualified) pension plans and  $60 million to our postretirement plans. During 2011, we expect to contribute from our general assets: a total of  $454 million to our international pension plans,  $406 million to our U.S. qualified pension plans,  $252 million to our postretirement plans and  $155 million to our U.S. supplemental (non-qualified) pension plans. Contributions expected to be made for 2011 are inclusive of amounts contributed during the first quarter of 2011. The international pension plan, postretirement plan and U.S. supplemental (non-qualified) pension plan contributions from our general assets include direct employer benefit payments.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet17.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings Per Share Attributable to Common Shareholders	3 Months Ended
Apr. 03, 2011
Earnings Per Share Attributable to Common Shareholders [Abstract]
Earnings Per Share Attributable to Common Shareholders [Text Block]	Note 13. Earnings Per Share Attributable to Common Shareholders Basic and diluted earnings per share (EPS) were computed using the following data:     Three Months Ended   (millions)   April 3, 2011     April 4, 2010                 EPS Numerator––Basic:             Income from continuing operations    $ 2,224      $ 2,014   Less: Net income attributable to noncontrolling interests     12       9   Income from continuing operations attributable to Pfizer Inc.     2,212       2,005   Less: Preferred stock dividends––net of tax     ––       1   Income from continuing operations attributable to Pfizer Inc. common shareholders     2,212       2,004   Discontinued operations––net of tax     10       21   Net income attributable to Pfizer Inc. common shareholders    $ 2,222      $ 2,025                     EPS Numerator––Diluted:                 Income from continuing operations attributable to Pfizer Inc. common shareholders and  assumed conversions    $ 2,212      $ 2,005   Discontinued operations––net of tax     10       21   Net income attributable to Pfizer Inc. common shareholders and assumed conversions    $ 2,222      $ 2,026                     EPS Denominator:                 Weighted-average number of common shares outstanding––Basic     7,982       8,061   Common-share equivalents: stock options, stock issuable under employee  compensation plans and convertible preferred stock     53       40   Weighted-average number of common shares outstanding––Diluted     8,035       8,101                     Stock options that had exercise prices greater than the average market price of our  common stock issuable under employee compensation plans(a)     290       366   (a) These common stock equivalents were outstanding during the first quarters of 2011 and 2010, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet18.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Legal Proceedings and Contingencies	3 Months Ended
Apr. 03, 2011
Legal Proceedings and Contingencies [Abstract]
Legal Proceedings and Contingencies [Text Block]	Note 14. Legal Proceedings and Contingencies As of March 31, 2011, Pfizer and its affiliated companies had settled, or entered into definitive agreements or agreements-in-principle to settle, approximately one-third of the hormone-replacement therapy actions pending against us and our affiliated companies. We have recorded aggregate charges with respect to those actions, as well as with respect to the actions that have resulted in verdicts against us or our affiliated companies, of  $172 million in the first quarter of 2011 and  $300 million in previous quarters. In addition, we have recorded a charge of  $300 million in the first quarter of 2011 that provides for the minimum expected costs to resolve all of the other outstanding hormone-replacement therapy actions against Pfizer and its affiliated companies, consistent with our current ability to quantify such future costs. The foregoing charges are estimates and, while we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for these contingencies given the uncertainties inherent in product liability litigation, additional charges may be required in the future. In January 2011, in a Multi-District Litigation (In re Neurontin Antitrust Litigation) that consolidates three actions, the U.S. District Court for the District of New Jersey certified a nationwide class consisting of wholesalers and other entities who purchased Neurontin directly from Pfizer and Warner-Lambert during the period from December 11, 2002 to August 31, 2008 and who also purchased generic gabapentin after it became available.  The complaints allege that Pfizer and Warner-Lambert engaged in anticompetitive conduct in violation of the Sherman Act that included, among other things, submitting applications for listing in the Orange Book and prosecuting and enforcing certain patents relating to Neurontin, as well as engaging in off-label marketing of Neurontin.  Plaintiffs seek compensatory damages, which may be subject to trebling.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet19.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment, Product and Geographic Information	3 Months Ended
Apr. 03, 2011
Segment, Product and Geographic Information [Abstract]
Segment, Product and Geographic Information [Text Block]	Note 15. Segment, Product and Geographic Area Information A. Segment Information We manage our operations through five operating segments––Primary Care (PC), Specialty Care and Oncology (SC&O), Established Products and Emerging Markets (EP&EM), Animal Health and Consumer Healthcare (AH&CH) and Nutrition (Nutri). Each operating segment has responsibility for its commercial activities and for certain research, development and medical safety activities. Previously, we managed our operations through two operating segments––Biopharmaceutical and Diversified. We regularly review our segments and the approach used by management to evaluate performance and allocate resources. A description of each of our five operating segments follows: ● Primary Care operating segment (PC)––includes revenues and earnings, as defined by management, from human pharmaceutical products primarily prescribed by primary-care physicians, and may include products in the following therapeutic and disease areas: Alzheimer’s disease, diabetes, cardiovascular (excluding pulmonary arterial hypertension), major depressive disorder, genitourinary, osteoporosis, pain and respiratory. Examples of products in this unit include Celebrex, Lipitor, Lyrica, Premarin, Pristiq and Viagra. All revenues and earnings for such products are allocated to the Primary Care unit, except those generated in emerging markets and those that are managed by the Established Products unit. ● Specialty Care and Oncology operating segment (SC&O)––comprises the Specialty Care business unit and the Oncology business unit.   ● Specialty Care––includes revenues and earnings, as defined by management, from human pharmaceutical products primarily prescribed by physicians who are specialists, and may include products in the following therapeutic and disease areas: antibacterials, antifungals, antivirals, bone, inflammation, growth hormones, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, psychosis and vaccines. Examples of products in this unit include, Enbrel, Genotropin, Geodon, the Prevnar/Prevenar franchise, Xalatan and Zyvox. All revenues and earnings for such products are allocated to the Specialty Care unit, except those generated in emerging markets and those that are managed by the Established Products unit.   ● Oncology––includes revenues and earnings, as defined by management, from human pharmaceutical products addressing oncology and oncology-related illnesses. Examples of products in this unit include Aromasin, Sutent and Torisel. All revenues and earnings for such products are allocated to the Oncology unit, except those generated in emerging markets and those that are managed by the Established Products unit. ● Established Products and Emerging Markets operating segment (EP&EM)––comprises the Established Products business unit and the Emerging Markets business unit.   ● Established Products––generally includes revenues and earnings, as defined by management, from human pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. Typically, products are transferred to this unit in the beginning of the fiscal year following losing patent protection or marketing exclusivity. In certain situations, products may be transferred to this unit at a different point than the beginning of the fiscal year following losing patent protection or marketing exclusivity in order to maximize their value. This unit also excludes revenues and earnings generated in emerging markets. Examples of products in this unit include Arthrotec, Effexor XR, Medrol, Norvasc, Protonix, Relpax and Zosyn/Tazocin.   ● Emerging Markets––includes revenues and earnings, as defined by management, from all human pharmaceutical products sold in emerging markets, including Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. ● Animal Health and Consumer Healthcare operating segment (AH&CH)—comprises the Animal Health business unit and the Consumer Healthcare business unit.   ● Animal Health––includes worldwide revenues and earnings, as defined by management, from products to prevent and treat disease in livestock and companion animals, including vaccines, paraciticides and anti-infectives.   ● Consumer Healthcare––generally includes worldwide revenues and earnings, as defined by management, from non-prescription medicines and vitamins, including products in the following therapeutic categories: GI-topicals, dietary supplements, pain management and respiratory. Examples of products in Consumer Healthcare are Advil, Caltrate, Centrum, ChapStick and Robitussin. ● Nutrition operating segment (Nutri)––generally includes revenues and earnings, as defined by management, from a full line of infant and toddler nutritional products sold outside of North America. Our chief operating decision maker uses the revenues and earnings of the five operating segments, among other factors, for performance evaluation and resource allocation. For the operating segments that comprise more than one business unit, a single segment manager is responsible for target setting, performance evaluation and resource allocation among those business units.   Certain costs are not allocated to our operating segment results, such as costs associated with the following: ● Worldwide Research and Development (WRD), which is generally responsible for human health research projects until proof-of-concept is achieved and then for transitioning those projects to the appropriate business unit for possible clinical and commercial development.  This organization also has responsibility for certain science-based platform services, which provide technical expertise and other services to the various research and development projects. ● Pfizer Medical (Pfizer Medical), which is responsible for all human-health-related regulatory submissions and interactions with regulatory agencies.  This organization is also responsible for the collection, evaluation and reporting of all safety event information related to our human health products and for conducting clinical trial audits and readiness reviews and for providing Pfizer-related medical information to healthcare providers. ● Corporate, which is responsible for platform functions such as finance, global real estate operations, human resources, legal, science and technology, worldwide procurement, worldwide public affairs and policy and worldwide technology. These costs include payroll charges and associated operating expenses, as well as interest income and expense. ● Certain transactions and events such as  (1) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (2) acquisition-related activities, where we incur costs for restructuring, integration, implementation and executing the transaction; and (3) certain significant items, which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and sales of assets or businesses. We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review asset information by operating segment and accordingly, we do not report asset information by operating segment. Total assets were approximately  $195 billion at April 3, 2011 and December 31, 2010. Certain information by operating segment follows:     Revenues     Earnings(a)       Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010   Primary Care    $ 5,441      $ 5,866      $ 3,546      $ 4,083   Specialty Care and Oncology     4,238       3,882       2,873       2,661   Established Products and Emerging Markets     4,545       4,758       2,490       2,992   Animal Health and Consumer Healthcare     1,727       1,509       489       397   Total reportable segments     15,951       16,015       9,398       10,133   Nutrition and other business activities(b)     551       561       (722 )     (793 ) Reconciling Items:                                 Corporate(c)     ––       ––       (1,660 )     (1,879 ) Purchase accounting adjustments(d)     ––       ––       (1,785 )     (2,839 ) Acquisition-related costs(e)     ––       ––       (575 )     (799 )     Certain significant items(f)     ––       ––       (1,208 )     (183 )     Other unallocated(g)     ––       ––       (330 )     (491 )      $ 16,502      $ 16,576      $ 3,118      $ 3,149   (a) Income from continuing operations before provision for taxes on income.   (b) Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization. (c) Corporate includes, among other things, administration expenses, interest income/(expense), certain performance-based and all share-based compensation expenses. (d) Significant impacts of purchase accounting include charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment. (e) Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity for additional information). (f) Certain significant items are substantive, unusual items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.   For the first quarter of 2011, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of  $572 million, (ii) charges for certain legal matters of  $472 million, (iii) certain asset impairment charges of  $157 million and (iv) other charges of  $7 million (see Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).   For the first quarter of 2010, certain significant items includes: (i) charges for certain legal matters of  $142 million, and (ii) other charges of  $41 million. (g) Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment. B. Product Information Significant product revenues follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010   Revenues from biopharmaceutical products:             Lipitor    $ 2,385      $ 2,757   Prevnar/Prevenar 13     996       286   Enbrel(a)     870       802   Lyrica     826       723   Celebrex     591       570   Viagra     470       479   XalatanXalacom     392       422   Norvasc     356       368   Zyvox     319       292   Sutent     276       259   Premarin family     235       256   Geodon/Zeldox     232       254   DetrolDetrol LA     225       261   Genotropin     209       206   Effexor XR     204       716   ChantixChampix     199       189   Vfend     195       188   ZosynTazocin     179       264   BeneFIX     164       154   PrevnarPrevenar (7-valent)     153       520   Caduet     142       135   Zoloft     135       120   Pristiq     129       110   ZithromaxZmax     128       103   Revatio     123       114   Medrol     121       109   ReFacto AFXyntha     117       90   Aromasin     114       128   Aricept(b)     99       107   Cardura     96       107   BMP2     93       98   Fragmin     91       90   Rapamune     89       91   Tygacil     73       84   Protonix     59       158   Alliance revenues(c)     884       1,004   All other     2,255       1,892   Total revenues from biopharmaceutical products     14,224       14,506   Revenues from other products:                 Animal Health     982       846   Consumer Healthcare     745       663   Nutrition     470       458   Pfizer CentreSource     81       103   Total revenues    $ 16,502      $ 16,576   (a) Outside the U.S. and Canada. (b) Represents direct sales under license agreement with Eisai Co., Ltd. (c) Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif, Spiriva and Metaxalone.   C. Geographic Area Information Revenues by geographic area follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010     % Change                       Revenues                   United States    $ 7,024      $ 7,265       (3 ) Developed Europe(a)     3,884       4,261       (9 ) Developed Rest of World(b)     2,546       2,302       11   Emerging Markets(c)     3,048       2,748       11   Total Revenues    $ 16,502      $ 16,576       ––   (a) Developed Europe region includes the following markets: Western Europe and the Scandinavian countries. (b) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet20.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of King Pharmaceuticals Inc (Table)	3 Months Ended
Apr. 03, 2011
Acquisition of King Pharmaceuticals Inc [Abstract]
Schedule Of Recognized Identifiable Assets Acquired And Liabilities Assumed As Part Of Business Combination [Text Block]	The following table summarizes the provisional recording, primarily at fair value, of the assets acquired and liabilities assumed as of the acquisition date:  (millions of dollars)   Amounts Recognized as of Acquisition Date (Provisional)           Working capital, excluding inventories    $ 210   Inventories     340   Property, plant and equipment     413   Identifiable intangible assets, excluding in-process research and development     1,781   In-process research and development     301   Net tax accounts     (384 ) All other long-term assets and liabilities, net     114   Total identifiable net assets     2,775   Goodwill     780   Net assets acquired/total consideration transferred    $ 3,555
Schedule Of Business Acquisition Included In Condensed Consolidated Statements Of Income [Text Block]	The following table presents information for King that is included in Pfizer’s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer’s first-quarter 2011 domestic and international quarter-ends:  (millions of dollars)   King’s Operations Included in Pfizer’s First Quarter 2011 Results           Revenues    $ 224   Loss from continuing operations attributable to Pfizer Inc. common shareholders(a)     (69 ) (a) Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ( $57 million pre-tax), amortization of identifiable intangible assets acquired from King ( $29 million pre-tax) and restructuring and integration costs ( $95 million pre-tax).
Schedule of pro forma information related to the acquisition [Text Block]	The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:     Pro Forma Consolidated Results       Three Months Ended   (millions of dollars, except per share  data)   April 3, 2011     April 4, 2010                 Revenues    $ 16,611      $ 16,949   Income from continuing operations attributable to Pfizer Inc. common shareholders     2,313       1,910   Diluted earnings per share attributable to Pfizer Inc. common shareholders     0.29       0.24

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet21.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Discontinued Operations (Table)	3 Months Ended
Apr. 03, 2011
Discontinued Operations [Line Items]
Schedule Of Disposal Groups Including Discontinued Operations Income Statement [Text Block]	The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations—net of tax in our Condensed Consolidated Statements of Income:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Revenues    $ 177      $ 174   Pre-tax income from discontinued operations    $ 28      $ 30   Provision for taxes     (18 )     (11 ) Income from discontinued operations––net of tax     10       19   Pre-tax gain on sale of discontinued operations     ––       3   Provision for income taxes     ––       (1 ) Discontinued operations––net of tax    $ 10      $ 21
Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet [Text Block]	The following assets and liabilities, which include assets and liabilities held for sale related to our Capsugel business, and other assets held for sale, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets: (millions of dollars)   April 3, 2011     Dec. 31, 2010                 Accounts receivable    $ 179      $ 186   Inventories     144       130   Taxes and other current assets     39       47   Property, plant and equipment     993       1,009   Goodwill     19       19   Identifiable intangible assets     6       3   Taxes and other noncurrent assets     45       45   Assets of discontinued operations and other assets held for sale    $ 1,425      $ 1,439                     Current liabilities    $ 133      $ 124   Other liabilities     49       27   Liabilities of discontinued operations    $ 182      $ 151

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet22.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Costs Associated with Cost-Reduction Initiatives and Acquisition Activity (Table)	3 Months Ended
Apr. 03, 2011
Costs Associated With Cost - Reduction Initiatives And Acquisition Activity [Abstract]
Schedule of costs in connection with cost-reduction initiatives and acquisition activity [Text Block]	We incurred the following costs in connection with our cost-reduction initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Transaction costs(a)    $ 10      $ 9   Integration costs(b)     179       208   Restructuring charges(c):                 Employee termination costs     667       458   Asset impairments     25       6   Other     13       25   Restructuring charges and certain acquisition-related costs     894       706     Additional depreciation––asset restructuring (d)                 Cost of sales     172       13   Selling, informational and administrative expenses     7       60   Research and development expenses     64       20   Total additional depreciation––asset restructuring     243       93     Implementation costs(e)                 Research and development expenses     10       ––   Total implementation costs     10       ––   Total costs associated with cost-reduction initiatives and acquisition activity    $ 1,147      $ 799   (a) Transaction costs represent external costs directly related to business combinations and primarily include expenditures for banking, legal, accounting and other similar services. (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and systems integration. (c) From the beginning of our cost-reduction and transformation initiatives in 2005 through April 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 53,500 employees, mainly in manufacturing and sales and research of which approximately 37,900 employees have been terminated as of April 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities. These restructuring charges in 2011 are associated with the following: Primary Care operating segment ( $46 million), Specialty Care and Oncology operating segment ( $35 million), Established Products and Emerging Markets operating segment ( $3 million), Animal Health and Consumer Healthcare operating segment ( $10 million), Nutrition operating segment ( $2 million), Worldwide Research and Development ( $422 million) and Corporate ( $187 million). (d) Additional depreciation – asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction initiatives.
Schedule of restructuring charges [Text Block]	The components of restructuring charges associated with all of our cost-reduction initiatives and acquisition activity follow:     Costs Incurred     Activity     Accrual   (millions of dollars)     2005-2011     Through April 3, 2011(a)     As of April 3, 2011(b)                         Employee termination costs    $ 9,478      $ 7,160      $ 2,318   Asset impairments     2,333       2,333       ––   Other     914       822       92   Total restructuring charges    $ 12,725      $ 10,315      $ 2,410   (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $1.7 billion) and Other noncurrent liabilities ( $700 million).

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet23.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Other (Income)/Deductions - Net (Table)	3 Months Ended
Apr. 03, 2011
Other (Income)/Deductions-Net [Abstract]
Schedule of Other (Income)/Deductions - Net [Text Block]	The following table sets forth details related to amounts recorded in Other deductions––net:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Interest income(a)    $ (105 )    $ (112 ) Interest expense(a)     458       522   Net interest expense     353       410   Royalty-related income     (171 )     (142 ) Net gain on asset disposals     (12 )     (45 ) Certain legal matters, net(b)     501       137   Certain asset impairment charges(c)     157       ––   Other, net     (1 )     52   Other deductions––net    $ 827      $ 412   (a) Interest income decreased in 2011 due to lower interest rates. Interest expense decreased in 2011 due to lower long- and short-term debt balances and the conversion of some fixed-rate liabilities to floating-rate liabilities. (b) In 2011, primarily relates to a charge for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies). (c) In 2011, relates to an IPR&D compound acquired as part of our acquisition of Wyeth.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet24.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income/(Loss) (Table)	3 Months Ended
Apr. 03, 2011
Comprehensive Income/(Loss) [Abstract]
Schedule Of Components Of Comprehensive Income [Text Block]	The components of comprehensive income/(loss) follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010                 Net income before allocation to noncontrolling interests    $ 2,234      $ 2,035   Other comprehensive income/(loss):                 Currency translation adjustment and other     1,541       (2,749 ) Net unrealized (losses)gains on derivative financial instruments     (135 )     134   Net unrealized losses on available-for-sale securities     (24 )     (15 ) Benefit plan adjustments     2       117   Total other comprehensive income(loss)     1,384       (2,513 ) Total comprehensive income/(loss) before allocation to noncontrolling interests     3,618       (478 ) Less: Comprehensive income(loss) attributable to noncontrolling interests     16       (10 ) Comprehensive income/(loss) attributable to Pfizer Inc.    $ 3,602      $ (468 )

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet25.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments (Table)	3 Months Ended
Apr. 03, 2011
Financial Instruments [Abstract]
Information about certain financial assets and liabiltiies [Text Block]	Information about certain of our financial assets and liabilities follows: (millions of dollars)   April 3, 2011     Dec. 31, 2010   Selected financial assets measured at fair value on a recurring basis (a) :             Trading securities    $ 155      $ 173   Available-for-sale debt securities(b)     29,482       32,699   Available-for-sale money market funds     1,396       1,217   Available-for-sale equity securities, excluding money market funds(b)     343       230   Derivative financial instruments in receivable positions(c):                 Interest rate swaps     339       603   Foreign currency swaps     268       128   Foreign currency forward-exchange contracts     134       494   Total     32,117       35,544   Other selected financial assets(d):                 Held-to-maturity debt securities, carried at amortized cost(b)     848       1,178   Private equity securities, carried at cost or equity method     1,156       1,134   Short-term loans, carried at cost     406       467   Long-term loans, carried at cost     237       299   Total     2,647       3,078   Total selected financial assets (e)    $ 34,764      $ 38,622   Financial liabilities measured at fair value on a recurring basis(a):                 Derivative financial instruments in a liability position(f):                 Foreign currency swaps    $ 572      $ 623   Foreign currency forward-exchange contracts     304       257   Interest rate swaps     7       4   Total     883       884   Other financial liabilities:                 Short-term borrowings, carried at historical proceeds, as adjusted(d), (g)     6,093       5,603   Long-term debt, carried at historical proceeds, as adjusted(h), (i)     35,308       38,410   Total     41,401       44,013   Total selected financial liabilities    $ 42,284      $ 44,897   (a) Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are  $109 million as of April 3, 2011 and  $105 million as of December 31, 2010 of investments that use Level 1 inputs in the calculation of fair value, and  $125 million that use Level 3 inputs as of April 3, 2011. (b) Gross unrealized gains and losses are not significant. (c) Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency swaps with fair values of  $70 million and foreign currency forward-exchange contracts with fair values of  $69 million at April 3, 2011; and foreign currency forward-exchange contracts with fair values of  $326 million and foreign currency swaps with fair values of  $17 million at December 31, 2010. (d) The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant at April 3, 2011 or December 31, 2010. (e) The decrease in selected financial assets is primarily due to sales of investments, the proceeds from which were used to fund our acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). (f) Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of  $107 million and foreign currency swaps with fair values of  $37 million at April 3, 2011; and foreign currency forward-exchange contracts with fair values of  $186 million and foreign currency swaps with fair values of  $93 million at December 31, 2010. (g) Includes foreign currency borrowings with fair values of  $920 million at April 3, 2011 and  $2.0 billion at December 31, 2010, which are used to hedge the exposure of certain foreign currency denominated net investments. (h) Includes foreign currency debt with fair values of  $838 million at April 3, 2011 and  $880 million at December 31, 2010, which are used to hedge the exposure of certain foreign currency denominated net investments. (i) The fair value of our long-term debt is  $38.7 billion at April 3, 2011 and  $42.3 billion at December 31, 2010.
Selected financial ssets and liabilities presented in the condensed consolidated balance sheets [Text Block]	These selected financial assets and liabilities are presented in the Condensed Consolidated Balance Sheets as follows: (millions of dollars)   April 3, 2011     Dec. 31, 2010   Assets             Cash and cash equivalents    $ 527      $ 906   Short-term investments     23,279       26,277   Short-term loans     406       467   Long-term investments and loans     9,811       9,747   Taxes and other current assets(a)     324       515   Taxes and other noncurrent assets(b)     417       710   Total selected financial assets    $ 34,764      $ 38,622   Liabilities                 Short-term borrowings, including current portion of long-term debt    $ 6,093      $ 5,603   Other current liabilities(c)     435       339   Long-term debt     35,308       38,410   Other noncurrent liabilities(d)     448       545   Total selected financial liabilities    $ 42,284      $ 44,897   (a) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $153 million), foreign currency forward-exchange contracts ( $134 million) and interest rate swaps ( $37 million) and at December 31, 2010, include foreign currency forward-exchange contracts ( $494 million) and foreign currency swaps ( $21 million). (b) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $115 million) and interest rate swaps ( $302 million) and at December 31, 2010, include interest rate swaps ( $603 million) and foreign currency swaps ( $107 million). (c) At April 3, 2011, derivative instruments at fair value include foreign currency forward-exchange contracts ( $304 million), foreign currency swaps ( $129 million) and interest rate swaps ( $2 million) and at December 31, 2010, include foreign currency forward-exchange contracts ( $257 million), foreign currency swaps ( $79 million) and interest rate swaps ( $3 million). (d) At April 3, 2011, derivative instruments at fair value include foreign currency swaps ( $443 million) and interest rate swaps ( $5 million) and at December 31, 2010, include foreign currency swaps ( $544 million) and interest rate swaps ( $1 million).
Contractual maturities of available-for-sale and held-to-maturity debt securities [Text Block]	The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 3, 2011, follow:     Years         (millions of dollars)   Within 1     Over 1 to 5     Over 10     Total at April 3, 2011   Available-for-sale debt securities:                         Western European and other government debt    $ 17,725      $ 969      $ ––      $ 18,694   Corporate debt     1,372       2,447       ––       3,819   Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities     ––       2,627       ––       2,627   Western European and other government agency debt     1,487       168       62       1,717   Supranational debt     937       647       ––       1,584   Reverse repurchase agreements     759       ––       ––       759   U.S. government Federal Deposit Insurance Corporation guaranteed debt     ––       155       ––       155   Other asset-backed securities     16       25       48       89   Certificates of deposit     38       ––       ––       38   Held-to-maturity debt securities:                                 Certificates of deposit and other     712       136       —       848   Total debt securities    $ 23,046      $ 7,174      $ 110      $ 30,330   Trading securities                             155   Available-for-sale money market funds                             1,396   Available-for-sale equity securities, excluding money market funds                             343   Total                            $ 32,224
Schedule of gains (losses) on interest rate risk [Text Block]	Information about gains/(losses) incurred to hedge or offset foreign exchange or interest rate risk is as follows:     Amount of Gains/(Losses) Recognized in OID(a) (b) (c)     Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a) (d)     Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a) (d)   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010   Three Months Ended                                     Derivative Financial Instruments in Fair Value   Hedge Relationships(b)                                      Interest rate swaps    $ ––      $ ––      $ ––      $ ––      $ ––      $ ––    Foreign currency swaps     (1 )     ––       ––       ––       ––       ––                                                     Derivative Financial Instruments in Cash Flow   Hedge Relationships                                                  Foreign currency swaps    $ ––      $ ––      $ 305      $ (438 )    $ 506      $ (628 )  Foreign currency forward-exchange contracts     ––       ––       2       ––       4       1                                                     Derivative Financial Instruments in Net   Investment Hedge Relationships                                                  Foreign currency swaps    $ 2      $ 1      $ 33      $ 11      $ ––      $ ––                                                     Derivative Financial Instruments Not   Designated as Hedges                                                  Foreign currency swaps    $ 30      $ 4      $ ––      $ ––      $ ––      $ ––    Foreign currency forward-exchange contracts     (197 )     (890 )     ––       ––       ––       ––                                                     Non-Derivative Financial Instruments in Net   Investment Hedge Relationships                                                  Foreign currency short-term borrowings    $ ––      $ ––      $ 43      $ 31      $ ––      $ ––    Foreign currency long-term debt     ––       ––       28       16       ––       ––                                                      Total    $ (166 )    $ (885 )    $ 411      $ (380 )    $ 510      $ (627 ) (a) OID = Other (income)/deductions—net, included in the income statement account, Other deductions—net. OCI = Other comprehensive income/(loss), included in the balance sheet account Accumulated other comprehensive loss. (b) Also includes gains and losses attributable to the hedged risk in fair value hedge relationships. (c) There was no significant ineffectiveness in the first quarters of 2011 or 2010. (d) Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Net unrealized (losses)/gains on derivative financial instruments. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Currency translation adjustment and other.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet26.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Table)	3 Months Ended
Apr. 03, 2011
Inventories [Abstract]
Schedule Of Components Of Inventories [Text Block]	The components of inventories follow: (millions of dollars)   April 3, 2011     Dec. 31, 2010                 Finished goods    $ 3,739      $ 3,665   Work-in-process     3,909       3,727   Raw materials and supplies     819       883   Total inventories(a)    $ 8,467      $ 8,275   (a) Certain amounts of inventories are in excess of one year’s supply. There are no recoverability issues associated with these quantities.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet27.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Goodwill and Other Intangible Assets (Table)	3 Months Ended
Apr. 03, 2011
Goodwill and Other Intangible Assets [Abstract]
Schedule of changes in carrying amount of goodwill [Text Block]	The changes in the carrying amount of goodwill for the three months ended April 3, 2011, follow: (millions of dollars)   Primary Care     Specialty Care and Oncology     Established Products and Emerging Markets     Animal Health and Consumer Healthcare     Nutrition     To be Allocated(a)     Total                                               Balance, December 31, 2010    $        $        $        $ 2,449      $ 496      $ 40,983      $ 43,928   Additions(b)                             ––       ––       780       780   Other(c)                             12       5       128       145   Balance, April 3, 2011    $        $        $        $ 2,461      $ 501      $ 41,891      $ 44,853   (a) The amount to be allocated includes the former Biopharmaceutical goodwill (see below), as well as newly acquired goodwill from our acquisition of King, for which the allocation to reporting units is pending (see Note 3. Acquisition of King Pharmaceuticals, Inc. for additional information). (b) Relates to our acquisition of King and is subject to change until we complete the recording of the assets acquired and liabilities assumed from King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). The allocation of King goodwill among our reporting units has not yet been completed, but will be completed within one year of the acquisition date. (c) Primarily reflects the impact of foreign exchange.
Schedule of identifiable intangible assets [Text Block]	The components of identifiable intangible assets follow:     April 3, 2011     December 31, 2010   (millions of dollars)   Gross Carrying Amount     Accumulated Amortization     Identifiable Intangible Assets, less Accumulated Amortization     Gross Carrying Amount     Accumulated Amortization     Identifiable Intangible Assets, less Accumulated Amortization                                         Finite-lived intangible assets:                                     Developed technology rights    $ 71,003      $ (28,029 )    $ 42,974      $ 68,432      $ (26,223 )    $ 42,209   Brands     1,635       (628 )     1,007       1,626       (607 )     1,019   License agreements     637       (277 )     360       637       (248 )     389   Trademarks and other     541       (337 )     204       533       (324 )     209   Total amortized finite-lived intangible assets     73,816       (29,271 )     44,545       71,228       (27,402 )     43,826   Indefinite-lived intangible assets:                                                 Brands     10,287       ––       10,287       10,219       —       10,219   In-process research and development     3,593       ––       3,593       3,438       —       3,438   Trademarks     72       ––       72       72       —       72   Total indefinite-lived intangible assets     13,952       ––       13,952       13,729       —       13,729   Total identifiable intangible assets(a)    $ 87,768      $ (29,271 )    $ 58,497      $ 84,957      $ (27,402 )    $ 57,555   (a) The increase is primarily related to the assets acquired as part of the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.) and the impact of foreign exchange, partially offset by amortization of intangible assets.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet28.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Pension and Postretirement Benefit Plans (Table)	3 Months Ended
Apr. 03, 2011
Pension and Postretirement Benefit Plans [Abstract]
Schedule of net periodic benefit costs of pension and post retirement benefit plans [Text Block]	The components of net periodic benefit costs of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, follow:     Pension Plans             U.S. Qualified     U.S. Supplemental (Non-Qualified)     International     Postretirement Plans   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010                                                     For the Three Months Ended:                                                 Service cost    $ 90      $ 94      $ 9      $ 8      $ 62      $ 60      $ 17      $ 22   Interest cost     185       191       19       19       111       111       49       54   Expected return on plan assets     (221 )     (202 )     ––       ––       (109 )     (112 )     (9 )     (8 ) Amortization of:                                                                    Actuarial losses     35       38       9       7       21       17       4       ––      Prior service credits     (2 )     ––       (1 )     (1 )     (1 )     (1 )     (14 )     (4 ) Curtailments and settlements––net     17       (33 )     12       (1 )     (2 )     1       (6 )     ––   Special termination benefits     5       14       7       90       3       1       ––       6   Net periodic benefit costs    $ 109      $ 102      $ 55      $ 122      $ 85      $ 77      $ 41      $ 70

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet29.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings Per Share Attributable to Common Shareholders (Table)	3 Months Ended
Apr. 03, 2011
Earnings Per Share Attributable to Common Shareholders [Abstract]
Schedule Of Earnings Per Share Basic By Common Class And Schedule Of Earnings Per Share Diluted By Common Class [Text Block]	Basic and diluted earnings per share (EPS) were computed using the following data:     Three Months Ended   (millions)   April 3, 2011     April 4, 2010                 EPS Numerator––Basic:             Income from continuing operations    $ 2,224      $ 2,014   Less: Net income attributable to noncontrolling interests     12       9   Income from continuing operations attributable to Pfizer Inc.     2,212       2,005   Less: Preferred stock dividends––net of tax     ––       1   Income from continuing operations attributable to Pfizer Inc. common shareholders     2,212       2,004   Discontinued operations––net of tax     10       21   Net income attributable to Pfizer Inc. common shareholders    $ 2,222      $ 2,025                     EPS Numerator––Diluted:                 Income from continuing operations attributable to Pfizer Inc. common shareholders and  assumed conversions    $ 2,212      $ 2,005   Discontinued operations––net of tax     10       21   Net income attributable to Pfizer Inc. common shareholders and assumed conversions    $ 2,222      $ 2,026                     EPS Denominator:                 Weighted-average number of common shares outstanding––Basic     7,982       8,061   Common-share equivalents: stock options, stock issuable under employee  compensation plans and convertible preferred stock     53       40   Weighted-average number of common shares outstanding––Diluted     8,035       8,101                     Stock options that had exercise prices greater than the average market price of our  common stock issuable under employee compensation plans(a)     290       366   (a) These common stock equivalents were outstanding during the first quarters of 2011 and 2010, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet30.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment, Product and Geographic Information (Table)	3 Months Ended
Apr. 03, 2011
Segment, Product and Geographic Information [Abstract]
Schedule of Segment Reporting Information by Segment [Text Block]	Certain information by operating segment follows:     Revenues     Earnings(a)       Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010     April 3, 2011     April 4, 2010   Primary Care    $ 5,441      $ 5,866      $ 3,546      $ 4,083   Specialty Care and Oncology     4,238       3,882       2,873       2,661   Established Products and Emerging Markets     4,545       4,758       2,490       2,992   Animal Health and Consumer Healthcare     1,727       1,509       489       397   Total reportable segments     15,951       16,015       9,398       10,133   Nutrition and other business activities(b)     551       561       (722 )     (793 ) Reconciling Items:                                 Corporate(c)     ––       ––       (1,660 )     (1,879 ) Purchase accounting adjustments(d)     ––       ––       (1,785 )     (2,839 ) Acquisition-related costs(e)     ––       ––       (575 )     (799 )     Certain significant items(f)     ––       ––       (1,208 )     (183 )     Other unallocated(g)     ––       ––       (330 )     (491 )      $ 16,502      $ 16,576      $ 3,118      $ 3,149   (a) Income from continuing operations before provision for taxes on income. (b) Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization. (c) Corporate includes, among other things, administration expenses, interest income/(expense), certain performance-based and all share-based compensation expenses. (d) Significant impacts of purchase accounting include charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment. (e) Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity for additional information). (f) Certain significant items are substantive, unusual items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.   For the first quarter of 2011, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of  $572 million, (ii) charges for certain legal matters of  $472 million, (iii) certain asset impairment charges of  $157 million and (iv) other charges of  $7 million (see Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).   For the first quarter of 2010, certain significant items includes: (i) charges for certain legal matters of  $142 million, and (ii) other charges of  $41 million. (g) Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.
Schedule of Revenue by Products [Text Block]	Significant product revenues follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010   Revenues from biopharmaceutical products:             Lipitor    $ 2,385      $ 2,757   Prevnar/Prevenar 13     996       286   Enbrel(a)     870       802   Lyrica     826       723   Celebrex     591       570   Viagra     470       479   XalatanXalacom     392       422   Norvasc     356       368   Zyvox     319       292   Sutent     276       259   Premarin family     235       256   Geodon/Zeldox     232       254   DetrolDetrol LA     225       261   Genotropin     209       206   Effexor XR     204       716   ChantixChampix     199       189   Vfend     195       188   ZosynTazocin     179       264   BeneFIX     164       154   PrevnarPrevenar (7-valent)     153       520   Caduet     142       135   Zoloft     135       120   Pristiq     129       110   ZithromaxZmax     128       103   Revatio     123       114   Medrol     121       109   ReFacto AFXyntha     117       90   Aromasin     114       128   Aricept(b)     99       107   Cardura     96       107   BMP2     93       98   Fragmin     91       90   Rapamune     89       91   Tygacil     73       84   Protonix     59       158   Alliance revenues(c)     884       1,004   All other     2,255       1,892   Total revenues from biopharmaceutical products     14,224       14,506   Revenues from other products:                 Animal Health     982       846   Consumer Healthcare     745       663   Nutrition     470       458   Pfizer CentreSource     81       103   Total revenues    $ 16,502      $ 16,576   (a) Outside the U.S. and Canada. (b) Represents direct sales under license agreement with Eisai Co., Ltd. (c) Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif, Spiriva and Metaxalone.
Schedule of Revenues by Geographic Area [Text Block]	Revenues by geographic area follow:     Three Months Ended   (millions of dollars)   April 3, 2011     April 4, 2010     % Change                       Revenues                   United States    $ 7,024      $ 7,265       (3 ) Developed Europe(a)     3,884       4,261       (9 ) Developed Rest of World(b)     2,546       2,302       11   Emerging Markets(c)     3,048       2,748       11   Total Revenues    $ 16,502      $ 16,576       ––   (a) Developed Europe region includes the following markets: Western Europe and the Scandinavian countries. (b) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet31.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Basis of Presentation (Detail) (USD  $)	Feb. 28, 2011 King [Member]	Jan. 31, 2011 King [Member]	Apr. 03, 2011 King US [Member]	Apr. 03, 2011 King International [Member]
Basis Of Presentation [Line Items]
Acquisition purchase price paid		$ 3,300,000,000
Percent of outstanding shares acquired		92.50%
Business acquisition additional payments	$ 300,000,000
Time period of King's operations included in parent's financial statements			P2M	P1M

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet32.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of King Pharmaceuticals Inc (Detail) (USD  $)	3 Months Ended		3 Months Ended
Apr. 03, 2011	Dec. 31, 2010	Apr. 03, 2011 King [Member]	Apr. 04, 2010 King [Member]	Feb. 28, 2011 King [Member]	Jan. 31, 2011 King [Member]	Apr. 03, 2011 Amounts Recognized as of Acquisition Date (provisional) [Member]
Business Acquisition Purchase Price
Acquisition Purchase Price Per Share						$ 14.25	$ 14.25
Percent of outstanding shares acquired							92.50%
Acquisition Purchase Price						$ 3,600,000,000
Total fair value of consideration transferred, net of cash acquired	3,169,000,000
Recording of Assets Acquired and Liabilities Assumed [Abstract]
Working capital, excluding inventories								210,000,000
Inventories								340,000,000
Property, plant and equipment								413,000,000
Identifiable intangible assets, excluding in-process research and development								1,781,000,000
In-process research and development								301,000,000
Net tax accounts								(384,000,000)
All other long - term assets and liabilities, net								114,000,000
Total identifiable net assets								2,775,000,000
Goodwill	44,853,000,000	[1]	43,928,000,000					780,000,000
Net assets acquired/total consideration transferred								3,555,000,000
Business Acquisition Narrative
Gross contractual amount receivable							200,000,000
Business Acquisition Included in Consolidated Statements of Income
Revenues				224,000,000
Loss from continuing operations attributable to Pfizer Inc. common shareholders				(69,000,000)
Footnote information
Purchase accounting adjustment for acquisition-date inventory estimated to have been sold, fair value				57,000,000	57,000,000
Purchase accounting adjustment for amortization of identifiable intangible assets acquired				29,000,000
Purchase accounting adjustment for restructuring and integration				95,000,000
Business Acquisition Pro Forma Information
Revenues				16,611,000,000	16,949,000,000
Income from continuing operations attributable to Pfizer Inc. common shareholders				2,313,000,000	1,910,000,000
Diluted earnings per share attributable to Pfizer Inc. common shareholders				$ 0.29	$ 0.24
Pro Forma Narrative
Elimination of intangible asset amortization				6,000,000	41,000,000
Additional amortization of intangible assets				14,000,000	43,000,000
Additional depreciation expense				1,000,000	3,000,000
Adjustment for acquisition-related costs				$ 117,000,000	$ 117,000,000
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet33.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Discontinued Operations (Detail) (USD  $) In Millions	3 Months Ended		3 Months Ended
Apr. 03, 2011	Apr. 04, 2010	Dec. 31, 2010	Apr. 03, 2011 Capsugel [Member]	Apr. 04, 2011 Capsugel [Member]
Discontinued Operations [Line Items]
Sale price for discontinued operation						$ 2,375
Quarter which the sale of discontinued operation is expected to be completed					Oct 2, 2011
Discontinued operations - net of tax in Condensed Consolidated Statements of Income:
Revenues	177		174
Pre-tax income from discontinued operations	28		30
Provision for taxes	(18)		(11)
Income from discontinued operations--net of tax	10		19
Pre-tax gain on sale of discontinued operations			3
Provision for income taxes			(1)
Discontinued operations - net of tax	10		21
Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations in Condensed Consolidated Balance Sheets:
Accounts receivable	179			186
Inventories	144			130
Taxes and other current assets	39			47
Property, plant and equipment	993			1,009
Goodwill	19			19
Identifiable intangible assets	6			3
Taxes and other noncurrent assets	45			45
Assets of discontinued operations and other assets held for sale	1,425	[1]		1,439
Current liabilities	133			124
Other liabilities	49			27
Liabilities of discontinued operations	$ 182	[1]		$ 151
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet34.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Costs Associated with Cost-Reduction Initiatives and Acquisition Activity (Detail) (USD  $) In Millions, unless otherwise specified	3 Months Ended	76 Months Ended
Apr. 03, 2011	Apr. 04, 2010	Apr. 03, 2011
Costs Associated with Cost-Reduction Initiatives and Acquisition Activity
Transaction costs	$ 10		$ 9
Integration costs	179		208
Restructuring charges:
Employee termination costs	667		458
Asset impairments	25		6
Other	13		25
Restructuring charges and certain acquisition-related costs	894		706
Additional depreciation-asset restructuring
Cost of sales	3,693	[1]	4,202	[1]
Selling, informational and administrative expenses	4,503	[1]	4,403	[1]
Research and development expenses	2,091	[1]	2,221	[1]
Total additional depreciation-asset restructuring	243		93
Total implementation costs	10
Total costs associated with cost-reduction initiatives and acquisition activity	1,147		799
Footnote information
Estimated Employee Terminations					53,500
Actual Employees Terminated	37,900				37,900
Additional depreciation asset restructuring [Member]
Additional depreciation-asset restructuring
Cost of sales	172		13
Selling, informational and administrative expenses	7		60
Research and development expenses	64		20
Total additional depreciation-asset restructuring	243		93
Implementation costs [Member]
Additional depreciation-asset restructuring
Research and development expenses	10
Primary Care operating segment [Member]
Footnote information
Restructuring charges	46
Specialty Care and Oncology operating segment [Member]
Footnote information
Restructuring charges	35
Established Products and Emerging Markets operating segment [Member]
Footnote information
Restructuring charges	3
Animal Health and Consumer Healthcare operating segment [Member]
Footnote information
Restructuring charges	10
Nutrition [Member]
Footnote information
Restructuring charges	2
Worldwide Research and Development [Member]
Footnote information
Restructuring charges	422
Corporate [Member]
Footnote information
Restructuring charges	$ 187
[1]	Exclusive of amortization of intangible assets, except as disclosed in Note 11.B Goodwill and Other Intangible Assets: Other Intangible Assets.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet35.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Costs Associated with Cost-Reduction Initiatives and Acquisition Activity - Restructuring Charges (Detail) (USD  $) In Millions	76 Months Ended
Apr. 03, 2011	Dec. 31, 2010
Restructuring charges:
Costs Incurred	$ 12,725
Activity	10,315
Accrual	2,410
Restructuring charges footnote information
Other current liabilities	15,338	[1]	14,256
Other noncurrent liabilities	4,970	[1]	5,601
Employee termination costs [Member]
Restructuring charges:
Costs Incurred	9,478
Activity	7,160
Accrual	2,318
Asset impairments [Member]
Restructuring charges:
Costs Incurred	2,333
Activity	2,333
Other [Member]
Restructuring charges:
Costs Incurred	914
Activity	822
Accrual	92
Restructuring Accrual [Member]
Restructuring charges footnote information
Other current liabilities	1,700
Other noncurrent liabilities	$ 700
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet36.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Other (Income)/Deductions - Net (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Other (Income) Deductions - Net [Line Items]
Interest income	$ (105)	$ (112)
Interest expense	458	522
Net interest expense	353	410
Royalty - related income	(171)	(142)
Net gain on asset disposals	(12)	(45)
Certain legal matters, net	501	137
Certain asset impairment charges	157
Other, net	(1)	52
Other deductions - net	$ 827	$ 412

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet37.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Taxes on Income (Detail)	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Income Taxes [Line Items]
Effective tax rate	28.70%	36.00%

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet38.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income/(Loss) (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Schedule of Comprehensive Income [Line Items]
Net income before allocation to noncontrolling interests	$ 2,234	$ 2,035
Other comprehensive income/(loss):
Currency translation adjustment and other	1,541	(2,749)
Net unrealized (losses)/gains on derivative financial instruments	(135)	134
Net unrealized losses on available - for - sale securities	(24)	(15)
Benefit plan adjustments	2	117
Total other comprehensive income/(loss)	1,384	(2,513)
Total comprehensive income/(loss) before allocation to noncontrolling interests	3,618	(478)
Less: Comprehensive income/(loss) attributable to noncontrolling interests	16	(10)
Comprehensive income/(loss) attributable to Pfizer Inc.	$ 3,602	$ (468)

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet39.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments Assets Measured on Recurring Basis (Detail) (USD  $) In Millions	Apr. 03, 2011	Dec. 31, 2010
Financial Assets Measured At Fair Value On Recurring Basis
Financial assets measured at fair value on a recurring basis	$ 32,117		$ 35,544
Other selected financial assets
Held - to - maturity debt securities, carried at amortized cost	848		1,178
Private equity securities, carried at cost or equity method	1,156		1,134
Short-term loans, carried at cost	406	[1]	467
Long-term loans, carried at cost	237		299
Total	2,647		3,078
Total selected financial assets	34,764		38,622
Footnotes to selected financial assets [Abstract]
Available - for - sale equity securities, excluding money market funds	343
Trading securities [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Financial assets measured at fair value on a recurring basis	155		173
Available - for - sale debt securities [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Financial assets measured at fair value on a recurring basis	29,482		32,699
Available - for - sale money market funds [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Financial assets measured at fair value on a recurring basis	1,396		1,217
Available - for - sale equity securities, excluding money market funds [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Financial assets measured at fair value on a recurring basis	343		230
Interest rate swaps [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Derivative assets measured at fair value on a recurring basis	339		603
Foreign currency swaps [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Derivative assets measured at fair value on a recurring basis	268		128
Footnotes to selected financial assets [Abstract]
Instruments used as offsets (assets)	70		17
Foreign currency forward-exchange contracts [Member]
Financial Assets Measured At Fair Value On Recurring Basis
Derivative assets measured at fair value on a recurring basis	134		494
Footnotes to selected financial assets [Abstract]
Instruments used as offsets (assets)	69		326
Fair value inputs Level 1 [Member]
Footnotes to selected financial assets [Abstract]
Available - for - sale equity securities, excluding money market funds	109		105
Fair value inputs Level 3 [Member]
Footnotes to selected financial assets [Abstract]
Available - for - sale equity securities, excluding money market funds	$ 125
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet40.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments Liabilities Measured on Recurring Basis (Detail) (USD  $)	Apr. 03, 2011	Dec. 31, 2010
Financial Liabilities Measured At Fair Value On Recurring Basis
Financial liabilities measured at fair value on a recurring basis	$ 883,000,000		$ 884,000,000
Other financial liabilities
Short - term borrowings, carried at historical proceeds, as adjusted	6,093,000,000	[1]	5,603,000,000
Long-term debt, carried at historical proceeds, as adjusted	35,308,000,000	[1]	38,410,000,000
Total	41,401,000,000		44,013,000,000
Total selected financial liabilities	42,284,000,000		44,897,000,000
Fair value of long term debt	38,700,000,000		42,300,000,000
Foreign currency forward-exchange contracts [Member]
Financial Liabilities Measured At Fair Value On Recurring Basis
Financial liabilities measured at fair value on a recurring basis	304,000,000		257,000,000
Other financial liabilities
Instruments used as offsets (liabilities)	107,000,000		186,000,000
Foreign currency swaps [Member]
Financial Liabilities Measured At Fair Value On Recurring Basis
Financial liabilities measured at fair value on a recurring basis	572,000,000		623,000,000
Other financial liabilities
Instruments used as offsets (liabilities)	37,000,000		93,000,000
Interest rate swaps [Member]
Financial Liabilities Measured At Fair Value On Recurring Basis
Financial liabilities measured at fair value on a recurring basis	7,000,000		4,000,000
Foreign currency debt used as hedging instrument [Member]
Other financial liabilities
Long-term debt, carried at historical proceeds, as adjusted	838,000,000		880,000,000
Foreign currency borrowings used as hedging instruments [Member]
Other financial liabilities
Short - term borrowings, carried at historical proceeds, as adjusted	$ 920,000,000		$ 2,000,000,000
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet41.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments by Balance Sheet Grouping (Detail) (USD  $) In Millions	Apr. 03, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 527		$ 906
Short-term investments	23,279	[1]	26,277
Short-term loans	406	[1]	467
Long-term investments and loans	9,811		9,747
Taxes and other current assets	324		515
Taxes and other noncurrent assets	417		710
Total selected financial assets	34,764		38,622
Liabilities
Short-term borrowings, including current portion of long-term debt	6,093	[1]	5,603
Other current liabilities	435		339
Long-term debt	35,308	[1]	38,410
Other noncurrent liabilities	448		545
Total selected financial liabilities	42,284		44,897
Foreign currency swaps [Member]
Assets
Taxes and other current assets	153		21
Taxes and other noncurrent assets	115		107
Liabilities
Other current liabilities	129		79
Other noncurrent liabilities	443		544
Interest rate swaps [Member]
Assets
Taxes and other current assets	37
Taxes and other noncurrent assets	302		603
Liabilities
Other current liabilities	2		3
Other noncurrent liabilities	5		1
Foreign currency forward-exchange contracts [Member]
Assets
Taxes and other current assets	134		494
Liabilities
Other current liabilities	$ 304		$ 257
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet42.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments Short and Long Term Debt (Detail) (USD  $) In Millions	Apr. 03, 2011	Dec. 31, 2010
Short - Term Borrowings
Short - term borrowings	$ 6,093	[1]	$ 5,603
Commercial Paper [Member]
Short - Term Borrowings
Short - term borrowings	$ 900		$ 1,200
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet43.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments-Investments in Debt and Equity Securities (Detail) (USD  $) In Millions	Apr. 03, 2011	Dec. 31, 2010
Held - to - maturity debt securities:
Held - to - maturity debt securities maturities total	$ 848	$ 1,178
Debt securities maturities within 1 year	23,046
Debt securities maturities over 1 to 5 years	7,174
Debt securities maturities over 10 years	110
Total debt securities	30,330
Trading securities	155
Available - for - sale money market funds	1,396
Available - for - sale equity securities, excluding money market funds	343
Total	32,224
Western European and other government debt [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	17,725
Available - for - sale debt securities maturities over 1 to 5 years	969
Available - for - sale debt securities maturities total	18,694
Corporate debt [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	1,372
Available - for - sale debt securities maturities over 1 to 5 years	2,447
Available - for - sale debt securities maturities total	3,819
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities over 1 to 5 years	2,627
Available - for - sale debt securities maturities total	2,627
Western European and other government agency debt [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	1,487
Available - for - sale debt securities maturities over 1 to 5 years	168
Available - for - sale debt securities maturities over 10 years	62
Available - for - sale debt securities maturities total	1,717
Supranational debt [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	937
Available - for - sale debt securities maturities over 1 to 5 years	647
Available - for - sale debt securities maturities total	1,584
Reverse repurchase agreements [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	759
Available - for - sale debt securities maturities total	759
US government Federal Deposit Insurance Corporation guaranteed debt [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities over 1 to 5 years	155
Available - for - sale debt securities maturities total	155
Other asset-backed securities [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	16
Available - for - sale debt securities maturities over 1 to 5 years	25
Available - for - sale debt securities maturities over 10 years	48
Available - for - sale debt securities maturities total	89
Certificates of deposit [Member]
Available - for - sale debt securities:
Available - for - sale debt securities maturities within 1 year	38
Available - for - sale debt securities maturities total	38
Certificates of deposit and other [Member]
Held - to - maturity debt securities:
Held - to - maturity debt securities maturities within 1 year	712
Held - to - maturity debt securities with maturities over 1 to 5 years	136
Held - to - maturity debt securities maturities total	$ 848

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet44.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financial Instruments-Derivative Financial Instruments and Hedging Activities (Detail) (USD  $)	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Derivative Financial Instruments and Hedging Activities
Aggregate notional amount of foreign exchange derivative financial instruments	$ 44,500,000,000
Aggregate notional amount of interest rate derivative financial instruments	13,000,000,000
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OID	(166,000,000)	(885,000,000)
Recognized in OCI	411,000,000	(380,000,000)
Reclassified from OCI to OID	510,000,000	(627,000,000)
Financial Instruments Narrative
Aggregate fair value of net derivative liabilities	297,000,000
Posted collateral	203,600,000
Additional collateral	93,900,000
Credit Risk
Concentration risk maximum exposure	3,100,000,000
Securities received as collateral	529,700,000
Fair Value Hedging [Member] | Foreign currency swaps [Member] | Other Income Expense [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OID	(1,000,000)
Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Reclassified from OCI to OID	4,000,000	1,000,000
Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OCI	2,000,000
Cash Flow Hedging [Member] | Foreign currency swaps [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Reclassified from OCI to OID	506,000,000	(628,000,000)
Cash Flow Hedging [Member] | Foreign currency swaps [Member] | Other Comprehensive Income [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OCI	305,000,000	(438,000,000)
Net Investment Hedging [Member] | Foreign currency swaps [Member] | Other Income Expense [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OID	2,000,000	1,000,000
Net Investment Hedging [Member] | Foreign currency swaps [Member] | Other Comprehensive Income [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OCI	33,000,000	11,000,000
Net Investment Hedging [Member] | Foreign currency short - term borrowings [Member] | Other Comprehensive Income [Member]
Non - Derivative Financial Instruments in Net Investment Hedge Relationships [Abstract]
Recognized in OCI	43,000,000	31,000,000
Net Investment Hedging [Member] | Foreign currency long - term debt [Member] | Other Comprehensive Income [Member]
Non - Derivative Financial Instruments in Net Investment Hedge Relationships [Abstract]
Recognized in OCI	28,000,000	16,000,000
Nondesignated [Member] | Foreign currency forward-exchange contracts [Member] | Other Income Expense [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OID	(197,000,000)	(890,000,000)
Nondesignated [Member] | Foreign currency swaps [Member] | Other Income Expense [Member]
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Recognized in OID	$ 30,000,000	$ 4,000,000

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet45.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Dec. 31, 2010
Inventories [Line Items]
Finished goods	$ 3,739		$ 3,665
Work - in - process	3,909		3,727
Raw materials and supplies	819		883
Total inventories	$ 8,467	[1]	$ 8,275
Footnote information [Abstract]
Inventory supply	Inventories are in excess of one year's supply
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet46.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Goodwill and Other Intangible Assets-Goodwill (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011
Changes in the carrying amount of goodwill
Balance, December 31, 2010	$ 43,928
Additions	780
Other	145
Balance, April 3, 2011	44,853	[1]
Animal Health and Consumer Healthcare [Member]
Changes in the carrying amount of goodwill
Balance, December 31, 2010	2,449
Other	12
Balance, April 3, 2011	2,461
Nutrition [Member]
Changes in the carrying amount of goodwill
Balance, December 31, 2010	496
Other	5
Balance, April 3, 2011	501
To be Allocated [Member]
Changes in the carrying amount of goodwill
Balance, December 31, 2010	40,983
Additions	780
Other	128
Balance, April 3, 2011	$ 41,891
King [Member]
Footnote information [Abstract]
Time period the allocation of King goodwill will be completed	P1Y
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet47.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Goodwill and Other Intangible Assets - Finite-lived and Indefinite-lived intangible assets (Detail) (USD  $)	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010	Dec. 31, 2010
Finite-lived intangible assets
Gross Carrying Amount	$ 73,816,000,000			$ 71,228,000,000
Accumulated Amortization	(29,271,000,000)			(27,402,000,000)
Identifiable Intangible Assets, less Accumulated Amortization	44,545,000,000			43,826,000,000
Indefinite-lived intangible assets
Indefinite-lived intangible assets brands	10,287,000,000			10,219,000,000
Indefinite-lived intangible assets in-process research and development	3,593,000,000			3,438,000,000
Indefinite-lived intangible assets trademarks	72,000,000			72,000,000
Total indefinite-lived intangible assets	13,952,000,000			13,729,000,000
Total identifiable intangible assets, less accumulated amortization	58,497,000,000	[1]		57,555,000,000
Intangible assets, gross carrying amount	87,768,000,000			84,957,000,000
Goodwill and Other Intangible Assets Narrative
Amortization expense for finite-lived intangible assets	1,400,000,000		1,400,000,000
Primary Care [Member] | Developed technology rights [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	17.00%
Nutrition [Member] | Developed technology rights [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	1.00%
Developed technology rights [Member]
Finite-lived intangible assets
Gross Carrying Amount	71,003,000,000			68,432,000,000
Accumulated Amortization	(28,029,000,000)			(26,223,000,000)
Identifiable Intangible Assets, less Accumulated Amortization	42,974,000,000			42,209,000,000
Developed technology rights [Member] | Specialty Care [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	62.00%
Developed technology rights [Member] | Oncology [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	1.00%
Developed technology rights [Member] | Established Products [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	17.00%
Developed technology rights [Member] | Animal Health [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	2.00%
Nutrition [Member] | Brands [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	22.00%
Brands [Member]
Finite-lived intangible assets
Gross Carrying Amount	1,635,000,000			1,626,000,000
Accumulated Amortization	(628,000,000)			(607,000,000)
Identifiable Intangible Assets, less Accumulated Amortization	1,007,000,000			1,019,000,000
Brands [Member] | Established Products [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	30.00%
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	27.00%
Brands [Member] | Animal Health [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	14.00%
Brands [Member] | Consumer Healthcare [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment	56.00%
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	51.00%
Licensing Agreements [Member]
Finite-lived intangible assets
Gross Carrying Amount	637,000,000			637,000,000
Accumulated Amortization	(277,000,000)			(248,000,000)
Identifiable Intangible Assets, less Accumulated Amortization	360,000,000			389,000,000
Trademarks and other [Member]
Finite-lived intangible assets
Gross Carrying Amount	541,000,000			533,000,000
Accumulated Amortization	(337,000,000)			(324,000,000)
Identifiable Intangible Assets, less Accumulated Amortization	$ 204,000,000			$ 209,000,000
Primary Care [Member] | In Process Research And Development [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	6.00%
Worldwide Research and Development [Member] | In Process Research And Development [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	18.00%
In Process Research And Development [Member] | Specialty Care [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	70.00%
In Process Research And Development [Member] | Oncology [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	3.00%
In Process Research And Development [Member] | Established Products [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	2.00%
In Process Research And Development [Member] | Consumer Healthcare [Member]
Goodwill and Other Intangible Assets Narrative
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment	1.00%
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet48.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Pension and Postretirement Benefit Plans (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
U.S. Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 90	$ 94
Interest cost	185	191
Expected return on plan assets	(221)	(202)
Amortization of:
Actuarial losses	35	38
Prior service credits	(2)
Curtailments and settlements - net	17	(33)
Special termination benefits	5	14
Net periodic benefit costs	109	102
Pension and Postretirement Benefit Plans Narrative
Contributions	400
Expected contributions in next fiscal year	406
U.S. Supplemental (Non-Qualified) [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	9	8
Interest cost	19	19
Amortization of:
Actuarial losses	9	7
Prior service credits	(1)	(1)
Curtailments and settlements - net	12	(1)
Special termination benefits	7	90
Net periodic benefit costs	55	122
Pension and Postretirement Benefit Plans Narrative
Contributions	92
Expected contributions in next fiscal year	155
International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	62	60
Interest cost	111	111
Expected return on plan assets	(109)	(112)
Amortization of:
Actuarial losses	21	17
Prior service credits	(1)	(1)
Curtailments and settlements - net	(2)	1
Special termination benefits	3	1
Net periodic benefit costs	85	77
Pension and Postretirement Benefit Plans Narrative
Contributions	121
Expected contributions in next fiscal year	454
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	17	22
Interest cost	49	54
Expected return on plan assets	(9)	(8)
Amortization of:
Actuarial losses	4
Prior service credits	(14)	(4)
Curtailments and settlements - net	(6)
Special termination benefits		6
Net periodic benefit costs	41	70
Pension and Postretirement Benefit Plans Narrative
Contributions	60
Expected contributions in next fiscal year	$ 252

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet49.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings Per Share Attributable to Common Shareholders (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
EPS Numerator - Basic:
Income from continuing operations	$ 2,224	$ 2,014
Less: Net income attributable to noncontrolling interests	12	9
Income from continuing operations attributable to Pfizer Inc.	2,212	2,005
Less: Preferred stock dividends - net of tax		1
Income from continuing operations attributable to Pfizer Inc. common shareholders	2,212	2,004
Discontinued operations - net of tax	10	21
Net income attributable to Pfizer Inc. common shareholders	$ 2,222	$ 2,025
EPS Denominator
Weighted - average number of common shares outstanding - Basic	7,982	8,061
Common share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock	53	40
Weighted - average number of common shares outstanding - Diluted	8,035	8,101
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans	290	366

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet50.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings Per Share Numerator Diluted (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
EPS Numerator - Diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$ 2,212	$ 2,005
Discontinued operations - net of tax	10	21
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$ 2,222	$ 2,026

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet51.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Legal Proceedings and Contingencies (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011
Legal Proceedings and Contingencies [Line Items]
Product liability charge	$ 172
Cumulative product liability charges	300
Product liability charge for the minimum expected costs to resolve outstanding actions	$ 300

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet52.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment, Product and Geographic Information (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010	Dec. 31, 2010
Revenues
Revenues	$ 16,502		$ 16,576
Earnings	3,118		3,149
Segment Revenues and Profit Loss Narrative
Certain legal matters, net	501		137
Certain asset impairment charges	157
Other charges	1		(52)
Total assets	194,956	[1]		195,014
Primary Care [Member]
Revenues
Revenues	5,441		5,866
Earnings	3,546		4,083
Specialty Care And Oncology [Member]
Revenues
Revenues	4,238		3,882
Earnings	2,873		2,661
Established Products and Emerging Markets [Member]
Revenues
Revenues	4,545		4,758
Earnings	2,490		2,992
Animal Health and Consumer Healthcare [Member]
Revenues
Revenues	1,727		1,509
Earnings	489		397
Total reportable segments [Member]
Revenues
Revenues	15,951		16,015
Earnings	9,398		10,133
Nutrition and other business activities [Member]
Revenues
Revenues	551		561
Earnings	(722)		(793)
Corporate [Member]
Revenues
Earnings	(1,660)		(1,879)
Purchase Accounting Adjustments [Member]
Revenues
Earnings	(1,785)		(2,839)
Acquisition-related costs [Member]
Revenues
Earnings	(575)		(799)
Certain significant items [Member]
Revenues
Earnings	(1,208)		(183)
Segment Revenues and Profit Loss Narrative
Restructuring charges and implementation costs associated with cost-reduction initiatives	572
Certain legal matters, net	472		142
Certain asset impairment charges	157
Other charges	7		41
Other unallocated [Member]
Revenues
Earnings	$ (330)		$ (491)
[1]	Unaudited.

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet53.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment, Product and Geographic Area Information - Revenues By Products (Detail) (USD  $) In Millions	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Significant product revenues are as follows:
Revenues	$ 16,502	$ 16,576
Biopharmaceutical [Member]
Significant product revenues are as follows:
Revenues	14,224	14,506
Lipitor [Member]
Significant product revenues are as follows:
Revenues	2,385	2,757
Prevnar / Prevenar 13 [Member]
Significant product revenues are as follows:
Revenues	996	286
Enbrel [Member]
Significant product revenues are as follows:
Revenues	870	802
Lyrica [Member]
Significant product revenues are as follows:
Revenues	826	723
Celebrex [Member]
Significant product revenues are as follows:
Revenues	591	570
Viagra [Member]
Significant product revenues are as follows:
Revenues	470	479
Xalatan / Xalacom [Member]
Significant product revenues are as follows:
Revenues	392	422
Norvasc [Member]
Significant product revenues are as follows:
Revenues	356	368
Zyvox [Member]
Significant product revenues are as follows:
Revenues	319	292
Sutent [Member]
Significant product revenues are as follows:
Revenues	276	259
Premarin family [Member]
Significant product revenues are as follows:
Revenues	235	256
Geodon / Zeldox [Member]
Significant product revenues are as follows:
Revenues	232	254
Detrol / Detrol LA [Member]
Significant product revenues are as follows:
Revenues	225	261
Genotropin [Member]
Significant product revenues are as follows:
Revenues	209	206
Effexor XR [Member]
Significant product revenues are as follows:
Revenues	204	716
Chantix / Champix [Member]
Significant product revenues are as follows:
Revenues	199	189
Vfend [Member]
Significant product revenues are as follows:
Revenues	195	188
Zosyn / Tazocin [Member]
Significant product revenues are as follows:
Revenues	179	264
BeneFIX [Member]
Significant product revenues are as follows:
Revenues	164	154
Prevnar / Prevenar (7-valent) [Member]
Significant product revenues are as follows:
Revenues	153	520
Caduet [Member]
Significant product revenues are as follows:
Revenues	142	135
Zoloft [Member]
Significant product revenues are as follows:
Revenues	135	120
Pristiq [Member]
Significant product revenues are as follows:
Revenues	129	110
Zithromax / Zmax [Member]
Significant product revenues are as follows:
Revenues	128	103
Revatio [Member]
Significant product revenues are as follows:
Revenues	123	114
Medrol [Member]
Significant product revenues are as follows:
Revenues	121	109
ReFacto AF/ Xyntha [Member]
Significant product revenues are as follows:
Revenues	117	90
Aromasin [Member]
Significant product revenues are as follows:
Revenues	114	128
Aricept [Member]
Significant product revenues are as follows:
Revenues	99	107
Cardura [Member]
Significant product revenues are as follows:
Revenues	96	107
BMP2 [Member]
Significant product revenues are as follows:
Revenues	93	98
Fragmin [Member]
Significant product revenues are as follows:
Revenues	91	90
Rapamune [Member]
Significant product revenues are as follows:
Revenues	89	91
Tygacil [Member]
Significant product revenues are as follows:
Revenues	73	84
Protonix [Member]
Significant product revenues are as follows:
Revenues	59	158
Alliance revenues [Member]
Significant product revenues are as follows:
Revenues	884	1,004
All other [Member]
Significant product revenues are as follows:
Revenues	2,255	1,892
Animal Health [Member]
Significant product revenues are as follows:
Revenues	982	846
Consumer Healthcare [Member]
Significant product revenues are as follows:
Revenues	745	663
Nutrition [Member]
Significant product revenues are as follows:
Revenues	470	458
Pfizer CentreSource [Member]
Significant product revenues are as follows:
Revenues	$ 81	$ 103

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/Sheet54.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment, Product and Geographic Area Information - Revenues By Geographic Area (Detail) (USD  $) In Millions, unless otherwise specified	3 Months Ended
Apr. 03, 2011	Apr. 04, 2010
Revenues by geographic area [Line Items]
Revenue by geographic area - United States	$ 7,024	$ 7,265
Total Revenues	16,502	16,576
Percentage Change In Revenue - United States	(3.00%)
Developed Europe [Member]
Revenues by geographic area [Line Items]
Revenue by geographic area - Foreign Countries	3,884	4,261
Percentage Change in Revenue - Foreign Countries	(9.00%)
Developed Rest Of World [Member]
Revenues by geographic area [Line Items]
Revenue by geographic area - Foreign Countries	2,546	2,302
Percentage Change in Revenue - Foreign Countries	11.00%
Emerging Markets [Member]
Revenues by geographic area [Line Items]
Revenue by geographic area - Foreign Countries	$ 3,048	$ 2,748
Percentage Change in Revenue - Foreign Countries	11.00%

------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215 Content-Location: file:///C:/165377b9_f79e_46e0_9bd7_0325dc1b8215/Worksheets/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" ------=_NextPart_165377b9_f79e_46e0_9bd7_0325dc1b8215--